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INTRODUCTION 
AUTOLOGOUS BONE MARROW TRANSPLANTATION 
Experimental studies on the therapeutic eradication of malignant cells 
showed a strong correlation between the dose of radiation or cytotoxic 
drugs and tumor cell kill (1,2,3) Also in men experience exists that 
the extent of tumor reduction depends on the intensity of the 
radio-chemotherapy applied. 
Further improvements of cancer therapy can be expected when therapy η s 
intensified, provided that the dose-intensification is tolerated One 
of the major limiting factors is the vulnerability of the bone marrow, 
which can be rendered aplastic by a more intensive cytotoxic therapy. 
The risks of prolonged or irreversible bone marrow suppression can be 
circumvented if a sufficient number of bone marrow stem cells is 
harvested before therapy, stored and rejnfused afterwards Such a 
procedure, known as an autologous bone marrow transplantation (ABMT), 
shortens the duration of the post-treatment aplasia due to rapid 
repopulation (4,5,6) 
Graft-versus-host disease and marrow-graft rejection, the major 
problems after allogeneic bone marrow transplantation, are avoided by 
the use of ABMT However, one of the major risks of ABMT is the 
presence of metastatic or residual malignant cells m the graft To 
achieve a cure the reinfused bone marrow should be free of disease. A 
variety of techniques (in vivo and in vitro) have been proposed for 
cleansing up the marrow from malignant cells The in vivo procedure 
consists of intensive cytoreductive therapy before bone marrow 
harvesting is performed This approach is not expected to eradicate 
all residual disease The in vitro methods include density separation 
(7), incubation with cytotoxic drugs (8,9) or the use of specific 
(monoclonal) antibodies These antibodies are used in either the 
presence of complement (10,11) or coupled with magnetic beads (12,13) 
or coupled with a cytotoxic substance (immunotoxins) (14). All 
methods carry the risk of a reduced bone marrow repopulation capacity 
due to damage and loss of stem cells 
The purpose of this study is to contribute to the safety of the 
procedure of ABMT by improving the technique and the quality 
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assessment Furthermore, possibilities are studied for in vitro 
selective kill of residual or metastatic malignant clonogenic cells in 
the bone marrow graft using cytotoxic drugs 
OUTLINE OF INVESTIGATIONS 
The objectives of this study are 1) to define the optimal procedures 
for bone marrow harvesting, volume reduction, progenitor cell 
enrichment, cryopreservation and thawing, 2) to investigate whether 
bone marrow can be cleansed up from contaminating leukaemic cells by 
m vitro incubation with c\toLoxic drugs, generall> in use for the 
treatment of leukemia 
In chapter 1 the procedures of bone marrow collection, removal of the 
bulk of erythrocytes and granulocytes, freezing and thawing of the 
marrow are described Clonogenic assd\s are applied for quality 
assessment of these different steps 
In chapter 2 a rapid and safe procedure to enrich the stem cells is 
described The enriched fraction contains almost no erythrocytes and 
granulocvtes and shows a capacity for complete hematologic 
repopulation 
In chapter 3 results of bone marrow repopulation after bone marrow 
ablative treatment and ADMT are presented for 11 patients with acute 
leukemia and 8 patients with a solid tumor 
In the second part of this thesis studies are described on 
differential sensitivity between normal and leukaemic clonogenic 
cells The effects of adriamycin (ADMI and cytosine arabinoside 
(Ara-C), two important drugs in the treatment of acute leukemia, are 
investigated In case of substantial differential sensitivity these 
drugs could be useful to eliminate residual clonogenic cells from bone 
marrow aspirates As no data were available about the optimal in 
vitro conditions for differential kill, the effect of exposure time 
and drug concentrations on in vitro sensitivity were determined for 
Ara-C (chapter U) and ADM (chapter 5) 
The results for differential kill with Ara-C in a model system, using 
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bone marrow cells mixed with clonogenic cells from a leukaemic cell 
line are presented in chapter 6. In the chapters 7 and 8 the results 
of studies on differential sensitivity between normal, and leukaemic 
clonogenic bone marrow cells from patients with acute nonlyraphocytic 
leukaemia to Ara-C and ADM are described. 
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CHAPTER 1 
ENRICHMENT AND CRYOPRESERVATION OF AUTOLOGOUS BONE MARROW 
R Raijmakers, Τ de Witte, F van den Ouweland, Ρ Geerdink, J Vessels, С 
Haanen 
Parts of this chapter have been published in: Cryobiology 1982 
19:292-298, The Netherlands Journal of Medicine 1983 26:67-73 and in 
"Autologous Bone Marrow Transplantation and Solid Tumors", EORTC 
monograph, volume 14, pages 5-8, Raven Press, New York, 1984. 
SUMMARY 
Bone marrow cryopreservation is a prerequisite for successful 
execution of autologous bone marrow reinfusion, since after prolonged 
storage at 4°C or at room temperature the viability decreases rapidly. 
Discontinuous cell centnfugation appears to offer a rapid and safe 
method to remove granulocytes, which after thawing induce cell 
clumping and cause cell damage and to reduce the volume of the 
aspirate, before cryopreservation (4,5) 
Freezing by a temperature-controlled program, storage at ultra-low 
temperature (-196GC) for longer periods, and subsequent thawing does 
not affect the viability of clonogenic progenitor cells (CFU-GM) 
The combination of buffy coat collection hy discontinuous 
centnfugation with controlled freezing in autologous plasma and 10oo 
dimethylsulfoxide (DMSO) resulted in an almost complete recovery of 
committed progenitor cells The procedure and the results of 
clonogenic assays of 107 сгуоргрьег\ed bone marrow samples are 
described 
INTRODUCTION 
Bone marrow suppression is one of the main limitations of intensive 
treatment of malignant diseases by chemotherapy and irradiation. The 
doses of irradiation and many cytotoxic drugs can be substantially 
escalated to more effective levels if autologous bone marrow 
transplantation (ABMT) is instituted (1). This technique, introduced 
already 25 years ago (2,3), is based on isolation and storage of bone 
marrow cells during cytotoxic treatment. 
Bone marrow progenitor cells survive for only a few days at A°C (4,5) 
This limitation of the storage time has been surpassed by the 
technique of bone marrow cryopreservation, stored at ultralow 
temperature (-1960C) the progenitor cells remain viable for years (6). 
PATIENTS AND METHODS 
PATIENTS 
Bone marrow was collected from 58 patients with acute leukaemia in 
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remission, 37 patients with a solid tumor and 12 patients with a 
malignant lymphoma. The ages ranged from 15 to 61 years, with a mean 
of 29.5 ± 10 years. In an attempt to minimize contamination of 
leukaemic cells, bone marrow of patients with leukaemia was harvested 
shortly after recovery from the last remission consolidation course. 
In all patients previously treated with cytotoxic drugs quantification 
of CFU-GM was performed to evaluate the presence of a sufficient 
number of clonogenic cells before the decision of bone marrow 
cryopreservation was made. 
METHODS 
Bone marrow aspiration. Bone marrow was collected under general or 
epidural anaesthesia by one hundred aspirations from the posterior 
iliac crests into 10 ml disposable syringes containing 1 ml acid 
citrate dextrose formula-A and 50 U preservative free heparin. Each 
aspirate of 10 ml was taken while the needle was repeatedly 
re-introduced through the cortex or after it was advanced further into 
the marrow cavity for at least one centimeter. Syringe contents were 
injected into a one liter plastic bag (Fenwal) through a 70 ym nylon 
filter fitted in a Swinnex-25 filter holder (Millipore). The whole 
aspiration procedure lasted about one hour. 
Bone marrow enrichment. The bone marrow aspirate was processed in a 
Haemonctics discontinuous cell separator (Haemonetics model 30, 
Haemonctics Corp., Natrick, Mass.) equipped with a 155 ml disposable 
pheresis set ("Paediatric Pheresis Set", list no 101). Red cell 
sedimentation was enhanced by addition of hydroxy-ethyl-starch 
(Plasmasteril, 6% HES, Fresenius, Bad Homburg, FRG); nine volumes of 
bone marrow aspirate were diluted with one volume HES. The plastic 
bag containing the cell suspension was connected with the pheresis 
set, the centrifuge was started and filled at a flow rate of 30 
ml/min. From the moment the buffy coat had reached the outflow 
aperture of the bowl the buffy coat was collected for 60 seconds in a 
plastic bag. The centrifuge was stopped and the bowl was emptied in 
the reinfusion bag of the pheresis set. This procedure was repeated 
until the total volume was processed. Subsequently the reinfusion bag 
was emptied in the original plastic bag and two additional, identical 
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runs were performed. During the third run plasma, needed for the 
cryopreservation, was collected separately. The whole procedure took 
about one hour and a half. 
For assessment of the optimal duration of the buffy coat collection 
and the need for additional runs, experiments were done during which 
0.5 ml samples were taken at the outlet port by means of a 3-way 
stopcock at intervals of 10 sec during the first and the third run. 
The buffy-coat-depleted erythrocyte suspension, containing 85™ of the 
original number of red cells, was reinfused into the patient within 3 
hours after bone marrow collection. 
Addition of dimethylsulfoxide (DMSO). The collected buffy coat 
fraction was centrifuged (15 min, 500 g, at A°C) and supernatant fat 
and plasma were removed to arrive at a volume of 100 ml. An equal 
volume of 20% (v/v) DMSO in cooled autologous plasma was added 
drop-wise to the cell suspension (placed on ice). The suspension was 
divided over two 100 ml Hemofrecze bags (Hemofreeze Bag DF 700, Gambro 
Dialisatoren GmbH & CoKg, Hechingcn, FRG) and 3 control vials (2ml 
vials, Nunc, Intermed, Denmark). 
Freezing program. The freezing procedure using a 
temperature-controlled apparatus (Nicool 416) has been previously 
described (1). The temperature during the freezing program was 
controlled by a probe placed in a dummy bag filled with plasma and 10% 
DMSO. After temperature equilibration of the freezing chamber (20 min 
at 7°C), temperature reduction was initiated at a rate of 200/ιηίη from 
70C to -S'C. At that point a programmed nitrogen supply was 
introduced in the freezing chamber to compensate the crystallization 
heat liberated at the phase-transition and a further temperature 
reduction to -70C. Temperature reduction after phase-transition was 
kept at 20C/min till -400C. Thereafter the temperature was reduced 
further at a rate of 50C/min till -ISO^C. The materials were stored 
in the vapour phase of liquid nitrogen. 
Thawing of bags. Bags were thawed by immersion in a 370C water bath 
and reinfused without any addition or further manipulation, through a 
filterless iv-system within 20 min before cell clumping occurred. 
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Thawing of test vials. Thawing is sustained badly by granulocytes 
Cell content released from lysed cells causes cell clumping within 30 
m m after thawing. This can be prevented by degradation of free DNA 
during a 10 min incubation in the presence of MgSO, with DNAse 
(deoxyribonuclease I, grade II from bovine pancreas, Boehrmger). 
Test vials were rapidly thawed in a 370C waterbath and diluted in 
fetal calf serum containing per ml: 70 U DNAse, 4 yM MgSO, and 5 U 
preservative free heparin The final cell concentration was brought 
to 7.106 cells/ml. 
Granulocyte-macrophage colony forming cell ICFU-GM) assay. All 
cultures were performed in 2 ml volumes in plastic Petri dishes 
(Costar), using Dulbecco's Modified Eagle's Medium (Flow) supplemented 
with 10» fetal calf serum from a preselected batch and 0.3% (w/v) 
Bacto-Agar (Difco). Nucleated cells were seeded in the presence of 5% 
(v/v) colony stimulating factor derived from human placenta, in the 
presence of endotoxin (HPCM-endo) (13,14). Duplicate cultures were 
incubated at 370C in a fully humidified atmosphere of 5% CO in air 
for 10-12 days. Cell aggregates consisting of 40 and more cells were 
scored as colonies and aggregates consisting of 3-40 cells as 
clusters. 
Statistics. The hilcoxon sign rank test was used to calculate 
statistical differences in the paired observations and in the 
comparison of different sources of CSF. If not stated otherwise all 
results are expressed as mean ± SD. 
RESULTS 
Collection of bone marrow. Bone marrow was collected from 107 
patients. The number of nucleated cells and CFl)-GM was in the same 
range for patients with acute leukaemia in remission (n=58) and those 
with solid tumors (n=49). The average number of collected nucleated 
cells was (19.6 ± 9.0)·'·109 containing (11.2 ± 11.8)-«106 CFU-GM for the 
9 
leukaemia patients and (19.5 ± 6.5)*10 nucleated cells with 
(7.6±4.1)*10 CFU-GM for the patients with solid tumors. The 
differences were not statistically significant. Data on all patients 
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are presented in table I The average volume of the bone marrow 
suspension was 925 ml Admixture of peripheral blood nucleated cells, 
calculated according to lloldrinet et al (15) was 23 ± 10°.. 
Table I Recovery after separation of bone marrow aspirates 
by discontinuous cell separation (n=107) 
Cells Aspirate Buffy coat Pellet Total 
fraction fraction recovery 
Nucl. Cells 
7 4+4.1 
38115 96125 
0 710.8 
9115 114149 
2 410.7 
73+17 91+18 
4 912.5 
47118 107164 
Discontinuous cell separation Samples taken at the outlet port of 
the cell separator were enriched for CFL.-GM. Compared with the 
unseparated marrow the percentage of CFL-GM increased from 100°o to 
312 1 53°o in the buffy coat collected during the first run for 60 sec 
(fig 1, run 1). The erythrocyte contamination in that buffy coat 
fraction was considerable, per m] buffy coat 7b 1 7% of the original 
number of red cells were present (fig 1, run I). 
9 
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Fig 1 : Distribution in the buffy coat of the bone 
marrow : CFU-GM CO), nucleated cells ( · ) and 
erythrocytes (L·). Samples uere taken at the 
outlet port every 10 sec. The number of cells in 
the original bone marrow was put on 100%. 
TWo additional runs on the pellet fraction after the first run still 
yielded CFU-GM enriched fractions (fig l,run III). For this reason 
bone marrow was separated 3 times in all experiments and the buffy 
coat from each run was collected for 60 sec. 
The buffy coat of 107 patients contained 101 ± 40% of the original 
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number of CFU-GM (table I) The number of erythrocytes was reduced to 
16 2 ± 8 0% and the number of granulocytes (bands and segmented forms) 
to 52 6 ± 22 О* of the starting material The loss of CFL-GM in the 
residual bone marrow suspension was 9 ± IS"» 
Drop-wise addition of the cryoprotectant DMSO, diluted in autologous 
plasma, to the bone marrow suspension did not influence neither the 
number of nucleated cells (95 ± 9 5°o) nor the viability of the 
clonogenic cells (101 ± 24 1°=) (n=23) 
Thawing of test vials A short incubation period (10 m m ) with DNAse 
was sufficient to prevent cell clumping, due to DNA strands released 
from damaged granulocytes Recovery of the nucleated cells after 
removal of DMSO and autologous plasma appeared to be 89 ± IS"» and 
recovery of CFU-GM 93 ± 20o„ (n=10) Prolongation of the incubation 
time to 120 m m resulted in a substantial loss of nucleated cells 
74 ± 18°*, (p<0 05) and CFU-GM 70 ± 25"„ (p<0 01) 
Removal of autologous plasma and DMSO was found to be necccssary for 
the in vitro assessment of the viabilit> of CFU-GM Plating 
efficiency was severely impaired if the thawed bone marrow was 
Table II Influence of different sources of CSF on recovery 
of CFU-GM after cryopreservation and thauing'" 
Recovery of CFl -GM Number of p-value 
°o observations 
CSF-CM feeder 
GCT 47±24 100±ч4 19 <0 05 
HPCM-endo 138+29 126+49 17 NS 
HPCM 47±20 92+20 4 <0 05 
•ТЛе value of CFU-GM before freezing was put at 100% 
The CSF activity of different conditioned media (CSF-CM) was 
compared with that of the peripheral blood mononuclear cells 
m a feeder layer (feeder) m pared experiments, using the 
same bone marrow samples each time 
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directly diluted in culture medium (n=6): 48 ± 29% compared with 
survival after two wash steps: 97 ± 37°ó (p<0.05). The source of 
colony-stimulating factor is critical for evaluation of the viability 
of CFU-GM after thawing. Recoveries of the CFU-GM after thawing 
assayed with Giant-Cell-Tumor derived colony stimulating factor 
(GCT-CSF) and HPCM were less than 50% (table II). CSF produced by 
peripheral blood mononuclear cells in a feeder layer yielded the best, 
but variable recovery. Recovery of the CFU-GM was complete and highly 
reproducable if assayed with CSF obtained from human placenta 
conditioned by E. Coli endotoxin. This was shown by a constant 
recovery of the CFU-GM: 103 ± 11?» from 18 test vials with bone marrow 
of one haematologically normal person thawed sequentially during a 
6-month period, while the double layer technique yielded variable 
results: 102 ± 65%. Recovery of the total number of CFU-GM after 
thawing was assessed in 46 patients and appeared to be 101 ± 31°» 
(table III). 
Table III. Survival of total number of CFU-GM after 
cryopreservation and thawing"·'·' 
Number of patients Recovery (%) 
CFU-GM (bags) 46 101131 
CFU-GM (bags) 9 97±17 
CFU-GM (vials) 9 116±36 
'*The results are based on the original value before 
addition of DtlSO, being equivalent to 100% 
In 9 patients the survival of CFU-GM from test vials and bags was 
compared and no differences were observed. Long term storage at 
ultralow temperature does not impair viability as is shown in fig 2; 
illustrating a survival of the CFU-GM for almost 2 years. 
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Fig 2: Survival of CFU-GM after storage at -ISo'C m relation 
to the storage time. Mean ± SD The number of observations in 
3 months periods is shown below each bar. 
DISCUSSION 
In the majority of patients with a solid tumor bone marrow was 
harvested before chemotherapy Despite heavy induction chemotherapy 
containing anthracylines and cytosine arabinoside for all patients 
with acute leukaemia, the collected number of nucleated cells and 
CFU-GM did not differ significantly in the group with acute leukaemia 
and that with solid tumours In fact the mean number of nucleated 
cells and CFU-GM was larger in the acute leukaemia group This may be 
due to the timing of the bone marrow harvest during the recovery phase 
from the remission consolidation courses Monitored by CFU-GM assays, 
the maximal number of clonogemc cells was observed in the recovery 
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phase, just before or shortly after the granulocyte number in the 
blood was restored to normal levels 
Discontinuous cell centrifugation was used for the removal of the 
majority of the erythrocytes and granulocytes Studies on the CFU-GM 
distribution in the buffy coat were performed to determine the optimal 
number and duration of buffy coat collections Three subsequent runs 
of the bone marrow aspirate through the cell separator with buffy coat 
collection from each run for 60 sec appeared optimal Recovery of the 
CFU-GM in the buffy coat collected from 107 bone marrow harvests was 
almost complete (101 ± 40",,) with only a minimal loss of 9 ± 15°» in the 
remainder The remainder, containing the majority of the 
erythrocytes, was reinfused to the patients within three hours of 
aspiration, thus avoiding the risks and costs of blood transfusion 
The risk of infectious contamination was minimized since the complete 
separation procedure was carried out m a closed system The duration 
of an average procedure was 1 5 hours and, unlike density gradient 
centrifugation (16), it required few laboratory skills and little 
effort 
The influences of the addition of the cryoprotectant D4IS0, the way of 
dilution and the incubation time with DNAse after thawing have been 
extensively assessed by in vitro culture assays The optimal 
conditions are presented The source of CSF appeared to be important 
Stimulation by CSF from peripheral blood mononuclear cells immobilized 
in a feeder layer yielded variable recovery after thawing The 
highest and most reproducable recovery was obtained using HPCM-endo 
Several recent studies (17,18) have shown suboptimal survival of 
CFU-GM after cryopreservation and thawing Three important reasons 
may explain the high levels of viability obtained with the method 
described the use of autologous plasma instead of culture medium, 
the programmed freezing monitored inside a reference bag instead of on 
the surface of the bag or inside the freezing chamber, and the use of 
a CSF source with a high activity (HPCM-endo) 
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CHAPTER 2 
ENRICHMENT OF HUMAN BONE MARROW ASPIRATES FOR LOWDENSITY MONONUCLEAR 
CELLS USING A HAEMONETICS DISCONTINUOUS BLOOD CELL SEPARATOR 
R Raijraakers, Τ de Witte, E Koekman, J Wessels, С Haanen 
In press: Vox Sanguinis 
SUMMARY 
Isopycnic density floatation centrifugation has been proven Lo be a 
suitable technique to enrich bone marrow aspirates for clonogenic 
cells on a small scale We have tested a Haemonetics discontinuous 
blood cell separator in order to process large volumes of bone marrow 
with minimal bone marrow manipulation The efficacy of isopycnic 
density floatation was tested in a one- and a two-step procedure 
Both procedures showed a recovery of about 20°„ of the nucleated cells 
and l-2\ of the erythrocytes The enrichment of clonogpnic colls in 
the one step procedure appeared superior to the two-step enrichment, 
first separating buffy coat cells The recovery of clonogenic cells 
was 67 ± 29 and 48 ± 19% respectively Repopulation capacity of the 
lowdensity cell fraction containing the clonogenic cells was excellent 
after autologous reinfusion (6 rases) and allogeneic bone marrow 
transplantation (3 cases) Fast enrichment of large volumes of bone 
marrow aspirates with lowdensity cells containing the clonogenic cells 
by isopycnic density floatation centrifugation can ho done safely 
using a Haemonetics blood cell separator 
INTRODUCTION 
To improve the potential of bone marrow transplantation, several 
techniques have been explored to deplete bone marrow aspirates of 
certain cell populations as for example Τ lymphocytes to prevent or 
mitigate graft-versus-host disease in illogoneic bone marrow 
transplantation or residual tumor cells in autologous reinfusion 
Most depletion techniques, eg the use of monoclonal antibodies [1], 
cytotoxic drugs [2] or physical separation [3], require a primary 
enrichment of bone marrow aspirates Isopycnic density separation for 
low-density cells (d < 1.070 g/ml) removes almost all erythrocytes and 
about 80°„ of the nucleated cells from the aspirates, without 
substantial loss of clonogenic cells [t] 
Density separation based on isopvcmc floatation centrifugation showed 
a higher recovery of clonogenic cells in the low-density cell fraction 
compared with isopycnic density sedimentation centrifugation [4] 
However, to process about 1 liter of bone marrow aspirate by isopycnic 
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floatation centrifugation, a large number of density gradients have to 
be made which includes a potential risk for bacterial contamination 
To circumvent these disadvantages the applicability of isopycnic 
floatation centrifugation in a Haemonetics semi continuous blood cell 
separator was tested 
PATIENTS, MATERIALS AND METHODS 
Patients Bone marrow aspirates from 21 patients, candidates for 
autologous reinfusion and 3 donors for allogeneic transplantation were 
processed Of the 21 patients 7 patients were in first complete 
remission of acute leukaemia and 14 patients had a solid tumor In 5 
patients with a solid tumor and 1 patient with a relapse of an acute 
lymphoblastic leukaemia the low-density marrow fraction was reinfused 
after bone marrow ablative chemotherapy 
Bone marrow aspiration Bone marrow was aspirated under general 
anaesthesia by multiple punctures from the posterior iliac crests in 
10 ml syringes containing 1 ml Acid Citrate Dextrose, formula-A, and 
50 U Heparin Syringe contents were filtered through a 70 цт nylon 
filter into a plastic transfer pack (Fenwal) up to a total volume of 
about 1 liter 
Cell enrichment in the Haemonetics centrifuge Two procedures to 
enrich low-density cells in the Haemonetics were compared In 
procedure (A) low-density cells were floatated from unseparated bone 
marrow Procedure (B) consisted of two consecutive separation steps 
in the Haemonetics, during the first step, buffy coat cells were 
collected, followed by isopycnic density floatation of the buffy coat 
cells as a second step 
A. One step enrichment of clonogenic cells. Bone marrow aspirates 
were centnfuged to remove plasma and fat. The residual plasma 
content of the cell suspension was determined by measurement of the 
celiente To obtain a density of 1.085 g/ml the cell suspension was 
diluted with calculated volumes of isotonic Percoli stock solution 
(Pharmacia, Uppsala, Sweden) (d 1 126 g/ml) and glucose phosphate 
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buffer (d 1.006 g/ml) to a final volume of 750 ml. The density of 
plasma was taken 1.025 g/ml. 
The Haemonetics was equipped with a 420 ml pheresis set (Boss phoresis 
set, list No 104, 375 ml bowl, Haemonetics, Soest, The Netherlands) 
The centrifuge was started (standard speed 4800 rpm/min) and filled at 
a flow rate of 30 ml/min with 70 ml glucose phosphate buffer, 100 ml 
Percoli (d 1.070 g/ml) and 250 ml of the cell suspension 
(d 1.085 g/ml). The filling procedure took about 15 min after which 
centrifugation was continued for another 20 min. Low-density cells 
moved upwards out of the 1.085 g/ml suspension to floatate on top of 
the Percoli 1.070 g/ml. The interphase cells were collected by 
pumping 100 ml Maxidens (d 1.900 g/ml, Nyegaard and Co, Oslo, Norway) 
into the bowl at a flow rate of 20 ml/min. Maxidens is a nontoxic 
autoclavable fluid which is immiscible with blood [7]. The total cell 
suspension of 750 ml was processed in three runs. 
B. Two step enrichment of clonogenic cells 
First step:• Buffy coat cells were obtained as has been described 
earlier [5,6]. In short: 9 volumes of bone marrow aspirate were 
diluted with 1 volume hydroxyethyl starch (plasmasteril, 6?, HES, 
Fresenius, Bad Homburg, FKG). The Haemonetics was equipped with a 155 
ml pheresis set (Boss pheresis set, list No 101, 100-ml bowl, 
Haemonetics, Soest, The Netherlands) After starting the centrifuge 
(4800 rpm/min), the cell suspension was pumped into the centrifuge at 
30 ml/min and from the moment the buffy coat had reached the outflow 
aperture it was collected during 60 sec in a plastic bag. The 
centrifuge was stopped and the. bowl was emptied in the reinfusion bag. 
This procedure was repeated until the total marrow aspirate was 
processed 3 times in about 9 runs. 
Second step:. The buffy coat fraction of about 250 ml was centrifuged 
and the supernatant plasma (ca 100 ml) was removed. The residual 
content of plasma was determined by measurement of the cellcrite. The 
cell suspension was diluted with Percoli stock solution and glucose 
phosphate buffer up to a volume of 250 ml and a density of 1.085 g/ral. 
The dilution of the marrow, ccntrifugation in the Haemonetics and the 
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collection of the low-density cells on the interphase were performed 
as described above. The total cell suspension was processed by one 
isopycnic density floatation centrifugation. 
Cell counts. Cell counts were performed with a Coulter Counter ZF 
(Coulter Electronics LTD., Dunstable Beds, UK) 
Granulocyte-macrophage colony forming cells (CFU-GH) assay. All 
cultures were performed in 2 ml volumes in plastic Petri dishes 
(Costar), using Dulbecco's modified Eagle's medium (Flow) supplemented 
with 20% heat-inactivated fetal calf serum from a preselected batch 
and 0.3 (w/v) Bacto-Agar (Difco). Nucleated cells were seeded in the 
presence of 5% (v/v) colony stimulating factor derived from human 
placenta, conditioned in the presence of endotoxin (HPCM-endo) [8,9]. 
Duplicate cultures are incubated at 370C in a fully humidified 
atmosphere of 5% C09 in air for 10-12 days. Aggregates consisting of 
40 and more cells are scored as colonies and aggregates consisting of 
3-40 cells as clusters. 
RESULTS 
Clonogenic cell enrichment 
One step procedure. In the low-density fraction of 8 aspirates 
separated by isopycnic density floatation in the Haemonetics, 17 ± 6% 
of the nucleated cells were recovered (table I). 
Red blood cells were reduced to 2.1 ± 2.4% of the original number. 
The recovery of CFU-GM in the low-density fraction was 67 ± 29?». In 
the pellet fraction 25 ± 18% of the CFU-GM were found. The total 
procedure took about 3 h. 
Two step separation procedure 
1. Buffy coat collection. The results of 16 buffy coat collections 
were not essentially different from earlier results; 61 ± 13% of the 
nucleated cells, 20 ± 7% of the red blood cells and 99 ± 29% of the 
CFU-GM were recovered in the buffy coat fraction (table II). 
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Table I Enrichment of bone marrow aspirates with nucleated 
cells and CFU-GM by floatation of low-density cells from 
unseparated bone marrow (mean ± SD, n=8). 
Cells Aspirate Low-density Pellet Total 
Fraction Fraction Recovery 
NC xlO9 
X 
CFU-GM xlO6 
X 
RBC xlO 1 2 
О 
/о 
24.1±3. 
100 
7.2±1 
100 
4.1±0 
100 
.8 
.8 
9 
4 2±1.8 
17±6.0 
4.411.8 
67±29 
0 1±0 1 
2.1±2.4 
17 4±4.0 
71±10 
1 8±1.5 
25±18 
3.9±1.0 
95±23 
89+10 
90±47 
97+28 
UC • nucleated cells, RBC- red blood cells 
The loss of CFU-GM in the pellet fraction was only 4V 
collection took about 1.5 h 
Buffy coat 
2. Isopycnic density floatation of the buffy coat cells. The 
floatation procedure following buffy coat separation showed further 
reduction of the nucleated cells from 61 ± 13% to 18 ± 5X and of the 
red blood cells from 20 ± 7% to 0.9 + 0.8% (table II). CFU-GM 
recovery was 48 ± 19% compared to 67 + 29% in the one step procedure. 
Part of the clonogenic cells were found in the pellet fraction of the 
floatation procedure (15 + 6%). The second step took also about 1.5 
h, including the centrifugation step needed to remove plasma from the 
buffy coat. This means that the total separation time for both the 
one-step and the two-step separation procedure was the same (3 h). 
Repopulating capacity. After bone marrow ablative chemotherapy, the 
low-density mononuclear cell fraction obtained by both methods gave 
repopulation results comparable to unseparated bone marrow (table 
III). Two patients with a solid tumor (1,2) and one patient with an 
acute lymphoblastic leukaemia (3), received bone marrow separated by 
floatation only (method A). Three other patients with a solid tumor 
ω 
Table II Enrichment of bone marrow aspirates for nucleated cells and CFU-GM by 2 consecutive separation 
steps (mean ± SD), (n=l6) 
Cells Aspirate Step 1:buffy coat collection Step 2:density floatation procedure overal I* 
recovery 
buffy coat pellet recovery light density pellet recovery 
fraction 
NC xlO 9 22.8±6.2 ik.0±k.3 7.1±3.6 3.9±1.9 7.9±4.0 
I 100 6l±13 31±13 92±9 18±5 39±17 90±1l| 88±10 
,6 
ω CFU-GM xlO 12.Ί±11.8 11.6±13.5 0.6±0.6 6.7±7.2 1.8±1.5 
% 100 99±29 ^±2 10ί»±29 48±19 15±6 67±8 77±1Α 
RBC xlO 1 2 3.2±0.5 0.6±0.2 2Л±0. 0.02±0.01 0.5±0.15 
% 100 20±7 72±13 90±12 0.9±0-8 Ì7±k 90±28 90±16 
NC = Nucleated cells, RBC = Red blood cells, * Recovery after the 2 consecutive separation steps 
Table III Patient data. Recovery after reinfusion of the low-density fraction obtained by isopycnic 
floatation of either bone marrow or buffy coat from bone marrow (see text). 
Patient Diagnosis Autologous Allogeneic Buffy coat Direct reinfusion data repopulation data 
no transplant transplant floatation floatation 
NC CFU-GM Leukoc* Thromboc* 
(xlO9) (xlO6) >1x109 >20x109 
(days) (days) 
+ 
+ 
+ 
+ 
+ 
+ 
¡i.2 
3.1 
3.5 
5.5 
2.4 
2.8 
2.7 
2.6 
0.8 
5.3 
2.0 
k.9 
1.8 
1.9 
э.ь 
10.3 
5.2 
NA 
25 
11» 
16 
22 
2k 
17 
39 
18 
21 
з<. 
13 
20 
28 
3Ί 
22 
2k 
20 
20 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Adenocarc. eci 
Seminoma testis 
ALL, remission 
Hodgkin lymphoma 
Ewing sarcoma 
Non Hodgkin 
ALL, remission 
ANLL,remission 
ALL, remission 
+ 
+ 
+ 
+ 
+ 
+ 
ALL = Acute lymphoblastic leukaemia, ANLL = Acute nonlymphocytic leukaemia, NC = Nucleated cells, 
NA = Not available, * The number of days before the cells increased above the indicated levels, 
Leucoc = Leucocytes, Thromboc - Thrombocytes. 
(4,5,6) were treated with low-density cells obtained after the 
two-step procedure (method B). The donor marrow of 3 candidates for 
allogeneic bone marrow transplantation was pre-separated with the 
Haemonetics by direct floatation and subsequently depleted from 
lymphocytes with elutriation centrifugation (8). The repopulation 
capacity was within normal ranges compared with other patients 
receiving whole marrow and methotrexate as graft versus host 
prophylaxis [1]. 
DISCUSSION 
Clonogenic cell enrichment of large volumes of bone marrow aspirates 
by isopycnic density floatation in a Haemonetics discontinuous blood 
cell separator has major advantages over a floatation procedure in 
centrifuge tubes. Manipulation of a great number of centrifuge tubes 
is very laborious and holds a potential risk for bacterial 
contamination compared with the system used in the Haemonetics. 
Two procedures of cell enrichment in the Haemonetics were compared, 
isopycnic density floatation of whole marrow aspirate and isopycnic 
density floatation after removing the majority of erythrocytes and 
part of the non-clonogenic nucleated cells by buffy coat 
centrifugation. The red cell contamination in the enriched fraction 
obtained by the two-step procedure was somewhat lower (0.9% versus 
2.1%). The recovery of the clonogenic cells was better (67 ± 29% 
versus 48 ± 19%) in the one-step procedure. The low-density fraction 
enriched by both procedures showed an unimpaired repopulation 
capacity. Better control of temperature during density floatation may 
improve separation results, as temperature influences fluid densities. 
Enrichment in the Haemonetics showed the sanie results as obtained with 
isopycnic density floatation on a small scale in centrifuge tubes [4], 
except for the recovery of clonogenic cells being lower in the 
fractions enriched by the Haemonetics (110% versus 48-67%). 
Ma and Biggs (10) described two methods to enrich stem cells: dextran 
sedimentation and buffy coat collection in a Haemonetics. The results 
obtained with these two methods are comparable with the Haemonetics 
buffy coat centrifugation method we described before [5,6]. The 
enrichment obtained with these methods is limited: part of red cells 
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(30-70?,,) and 20-40°,, of the nucleated cells are removed. In the cell 
fraction enriched with low-density cells, a more than 80°» reduction of 
nucleated cells is obtained and almost all erythrocytes are eliminated 
(98-99%). 
Data on bone marrow enrichment with low-density cells using a 
Ficoll-Metrizoate density separation in an IBM 2991 blood cell 
processor have been published by Gilmore et al [11] Their results 
are comparable with our data obtained by floatation centnfugation in 
the Haemonetics with respect to red cell elimination (99°,,) and 
recovery of mononuclear cells (18°. with the Haemonetics, 25°o with the 
IBM). Clonogenic cell recovery seems to be better with the IBM, 109^ , 
compared to 67л in the Haemonetics, but with a considerable range, 
53-170°., while data on the loss of clonogenic cells in the pellet 
fraction were not given. 
Enrichment of low-density cells is a prerequisite for the different 
purging techniques which may become of increasing importance in 
allogeneic and autologous bone marrow transplantation. Reduction in 
the volume and number of cells will allow a more efficient use of 
immunotoxins or cytotoxic drugs in the removal of residual tumor cells 
or other target cells such as T-lymphocytes for the prevention of 
graft versus host disease. 
Enrichment of large volumes of bone marrow aspirates with low-density 
mononulear cells can be performed with a Haemonetics discontinuous 
blood cell separator Both described procedures showed an unimpaired 
repopulation capacity, but floatation of whole bone marrow appeared 
preferable. 
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CHAPTER 3 
AUTOLOGOUS BONE MARROW TRANSPLANTATION AFTER BONE MARROW ABLATIVE 
RADIO-CHEMOTHERAPY IN ACUTE LEUKAEMIA AND SOLID TUMORS 
R Raijmakers, Τ de Witte, J Wessels, С Haanen 
SUMMARY 
Eleven patients with acute leukaemia and 8 patients with solid tumors 
were treated with high dose radio-chemotherapy and autologous bone 
marrow transplantation (ABMT) as rescue for bone marrow toxicity. 
Out of the three patients with acute leukaemia treated while in 
relapse two attained a complete remission (CR), but all of them died 
within 7 weeks after ABMT. Four patients, who received the treatment 
as an intensive consolidation course in second or third CR recovered 
completely, three of them are still in CR (10+, 9+, 4.5+ months) and 
one patient relapsed after 13 months. 
A third group of four patients in first CR, but with a high risk of 
relapse was given bone marrow ablative treatment as consolidation of 
CR. All of them recovered, three patients are still in CR (1+, 5+ and 
7+ months), one patient died in CR after 4 months. 
Eight patients with solid tumors underwent ABMT and all showed 
complete bone marrow recovery. In three patients with a large tumor 
load, reduction and temporary stabilisation of tumor growth was 
obtained. Three patients who were treated after surgical debulking of 
tumor relapse showed a temporary response ranging from 1 to 4 months. 
In two patients with a Hodgkin's disease the bone marrow ablative 
treatment appeared effective; in one patient a CR was obtained for 2 
months, in a relapsed patient the second CR was consolidated by ABMT 
and persists now for 10+ months. 
In the 19 patients treated with ABMT defective repopulation was 
observed in one patient, who died from a bleeding after persistent 
thrombocytopenia. One patient died 5 days after ABMT due to a 
bleeding and a third patient died from an infectious complication 
after the bone marrow had already been repopulated. Three patients, 
treated in relapse of their acute leukaemia, received a rather low 
4 
number of CFU-GM (< 2.10 CFü-GM/kg). The 16 patients receiving more 
4 
than 2.10 CFU-GM/kg all showed complete recovery of their bone marrow 
function. The repopulation time in these patients did not correlate 
with the number of CFU-GM reinfused. 
ABMT has shown to be a safe procedure provided that an adequate number 
of stem cells is given. Antitumor effect was of limited value in the 
more advanced stages of the disease. Therefore ABMT should be 
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restricted to early stages of the disease. 
INTRODUCTION 
Autologous bone marrow transplantation (ABMT) is a method to 
circumvent the dose-limiting cytotoxic effect of radio-chemotherapy on 
normal bone marrow (1). The principle of isolation of bone marrow 
before initiating cytotoxic therapy and reinfusion thereafter has been 
applied already 25 years ago (2,3). The practical application has 
increased after adequate bone marrow storage facilities became 
available. Progenitor cells survive for only a feu days when stored 
at Д'С (4,5). Cryopreservation has surpassed this limitation, stored 
at ultralow temperature the viability of the progenitor cells remains 
for years (6). 
Based on the dose-related response to irradiation and a number of 
chemotherapeutic drugs, bone marrow ablative radio-chemotherapy 
followed by ABMT has been applied in acute leukaemias, lymphomas and 
solid tumors like neuroblastoma, Ewmg sarcoma, testicular and other 
germ cell carcinoma's and small cell carcinoma of the lung (7). Also 
in a number of malignancies poorly responsive to conventional 
treatment this treatment modality has been applied, such as melanoma, 
breast cancer, gastro-intestinal carcinomas and glioblastoma 
multiforme (7). 
In this paper the results of ablative chemotherapy followed by ABMT 
are described for 11 patients uith acute leukaemia and 8 patients with 
a solid tumor. 
PATIENTS AND METHODS 
After bone marrow ablative therapy 11 patients with acute leukaemia 
and 8 patients with a solid tumor were rescued by reinfusion of 
autologous, previously cryopreserved bone marrow (table I) b3 The 
patients with acute leukaemia can be divided in three categories: 
1. Three patients (nrs. 1,2,3) were treated with bone marrow 
ablative therapy while in relapse, patient nr 1 and nr 2 received 
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Table I Clinical data 
Patient 
no 
1 
2 
3 
k 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Sex 
F 
F 
M 
M 
F 
M 
F 
M 
M 
F 
M 
M 
M 
F 
M 
M 
M 
F 
M 
Age 
21 
41 
61 
31 
19 
17 
20 
28 
17 
32 
31 
36 
22 
36 
28 
20 
25 
29 
34 
Diagnosi s 
ANLL 
ANLL 
ANLL 
ANLL 
common-ALL 
T-ALL 
ANLL 
T-ALL 
T-ALL 
ANLL 
Plasma cel 1 leuk 
Pleural Adenocarc 
Coloncarc 
Ovarian Care 
Seminoma Testis 
Testis care 
Ewing sarcoma 
Hodgkin lymphoma 
Hodgkin lymphoma 
Clinical state 
first relapse 
first relapse 
first relapse 
second CR 
third CR 
second CR 
second CR 
first CR 
first CR 
first CR 
first CR 
lung metast 
Abdominal mass 
Abdominal mass 
Med ¡asti η mass 
retroperit mass 
lung metast 
partial remis 
second CR 
Treatment scheme 
Cy Adr TBI 900cG 
Cy Adr TBI 900cG 
D A Vincr Ams Τ 
Bu Су 
Bu Су 
Bu Су 
Bu Су 
Cy TBI 800cG 
Cy TBI 800cG 
Cy Vp TBI 900cG 
Me (2 courses) 
CC Vin Mtx Adr Cy 
Me Adr + 5-FLI ip 
Me 
Iph Vp 
Iph Vp 
Me (2 courses) 
ВС Vp Α-high dose 
ВС A Су Τ 
Response 
second CR 
not évaluable 
second CR 
consol¡dation 
consol¡dation 
consol¡dation 
consi1¡dation 
consol¡dation 
consol¡dation 
consol¡dat¡on 
consol¡dation 
stable disease 
partial resp 
partial resp 
partial resp 
partial resp 
partial resp 
CR 
consol¡dation 
Durât¡on 
respone* 
4 
7 
10 
9 
4, 
13 
7 
2 
5 
2 
6 
3 
3 
3 
7 
4 
2 
10 
wks 
wks 
mo+ 
mo+ 
.5 mo+ 
mo 
mo+ 
wks+ 
mo+ 
mo 
mo 
mo 
years+ 
wks 
wks 
mo 
mo 
mo+ 
Survival 
4 
5 
7 
19 
4 
8 
4, 
6, 
7 
2 
12 
wks 
days 
wks 
mo+ 
mo 
mo 
,5 mo 
.5 mo 
mo 
years+ 
mo 
ANLL= Acute nonlymphocytic leukaemia, ALL= Acute lymphocytic leukaemia, CR= complete remission, mo= та. 
wks= weeks, *= duration of response indicated with + = still continuing on date evaluation. _ 
Cy= Cyclophosphamide 50 mg/kg, 4 days; Adr= Adriamycin 60 mg/m», 1 day; D= Daunovubicin 60 mg/m , 3?ά 
A= Cytosine Arabinoside 200 mg/m , 4 days; Α-high dose- 6 g/m , 4 days; Vincr= Vincristine l.S g/m , 
Bu= Busulfan 2 mg/kg, 4 days; Vin= Vindesine 3 mg/m , 1 day; Ams= m-AMSA 250 mg/m , 1 day; T= 6-Thiogb 
200 mg/m , 1 day; Vp= Etoposide 600 mg/m , Ζ days; CC= CCNU 200 mg/m , l2day; Mtx= Methotrexate 40 mg/ 
1 day; Iph= Iphosphamide 60 mg/kg, 4 days; 5-FU= 5-Fluoruracil 1000 mg/m , 4 days,intraperitoneal; 
Me= Melphalan 180 mg/m , 1 day. TBI= Total body irradiation, cG= centiGray. 
ths 
s; 
day 
nin 
cyclophosphamide, adriamycin and total body irradiation (TBI) and 
patient nr 3, because of his age, only intensive combination 
chemotherapy 
2. Four patients (nrs 4,5,6,7) with a relapsed acute leukaemia were 
first brought into a second or third CR and subsequently treated with 
high dose busulfan and cyclophosphamide followed by ABMT. 
3. Four patients (nrs 8,9,10,11) were treated in first CR with bone 
marrow ablative therapy and ABMT because of high grade malignancy 
Two of them (nrs 8,9) with T-cell acute lymphoblastic leukaemia 
(T-ALL) were rescued by autologous bone marrow after T-cell purging 
with an immunotoxin (WT-1 monoclonal antibody conjugated with ncin-A 
chains) (8) Patient nr 10 had an acute nonlymphocytic leukaemia 
(ANLL) with skin localisation After a CR was obtained she was 
treated with skin irradiation as adjuvant therapy followed by high 
dose consolidation therapy and ABMT. Patient nr 11 with plasma cell 
leukaemia was treated with two consecutive high dose melphalan courses 
and subsequent ABMT. 
Eight patients treated for a solid tumor can be divided in 3 
categories according to the stage of their disease. 
1. Two patients (nrs 12,13) with an adenocarcinoma and one patient 
(nr 14) with an ovary carcinoma received ablative therapy for a 
considerable tumor mass In patient nr 14 an abdominal mass existed 
despite treatment with six courses combination chemotherapy 
(cis-platin, adriamycin, cyclophosphamide) 
2. Three patients (nrs 15,lb,17) were treated with bone marrow 
ablative chemotherapy and ABMT after the tumor load had been reduced 
by surgical debulking All three patients had been treated before 
with conventional chemotherapy regimens Patient nr 18 had residual 
Hodgkin's disease after MOPP and ABVD polychemotherapy and 
irradiation. 
3. One patient (nr 19) was treated with high dose chemotherapy and 
ABMT as intensive consolidation during a second CR of a Hodgkm's 
disease(9). 
Bone Marrow Reinfusion Bone marrow was aspirated, enriched for 
clonogemc cells with use of a cell separator and stored in liquid 
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nitrogen as described previously (6,10). The number of nucleated 
cells and CFU-GM were measured before cryopreservation and after 
thawing in control vials as well as in the bags. The bags were thawed 
in a waterbath at 370C and, after a sample was taken to determine the 
number of CFU-GM, the bone marrow was rcinfused immediately through a 
filterless intravenous infusion system. 
The time of hypoplasia was defined as the number of days the leucocyte 
9 
count was less than 1x10 /1 and/or the thrombocyte count less than 
9 
20x10 /1 without support. For both the leucocytes and the 
thrombocytes the correlation between the duration of hypoplasia and 
the number of CFU-GM infused was evaluated. 
RESULTS 
The response, the duration of response and the survival after bone 
marrow ablative therapy followed by ΛΒΜΤ are presented in table I. 
Two of the 3 patients with acute leukaemia treated while in relapse 
(group 1) obtained a CR. Patient nr 1 attained a normal, but 
hypoplastic bone marrow with virtually absence of megakaryocytes. She 
died of a cerebral hemorrhage after she had become refractory to 
random and family donor platelet transfusions. Patient nr 2 died in 
aplasia from a gastro-intestinal bleeding 5 days after ABMT. Patient 
nr 3 died 7 weeks after ΛΒΜΤ due to an infectious complication with 
normal bone marrow and peripheral blood values. 
None of the 8 patients with acute leukaemia treated with ABMT while in 
CR (group 2 and 3) died in aplasia. One patient (nr 7) relapsed 13 
months after the ABMT. Three of the 4 patients in whom bone marrow 
ablative therapy and ABMT was performed in first CR (group 3) are 
still in CR. One patient (nr 11) received an allogeneic bone marrow 
transplantation after 2 consecutive ABMT's. He died during the 
aplastic phase of the allogeneic bone marrow transplantation. 
All eight patients with a solid tumor survived the intensive treatment 
followed by ABMT and their peripheral blood values normalized 
completely (table I). The intensive treatment schemes were effective 
in tumor reduction in all but one case (nr 17, second ABMT). 
Unfortunately the duration of the response was short in most patients. 
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Table II Number of nucleated cells collected and reinfused and repopulation data 
7 ¡J Ц 
Patient Chemotherapy Storage NC xlO/kg CFU-GM xlO /kg CFU-GM xIO /kg Repopulation data 
Dgc" leukoç* 
ι" /ι 
before time reinfused collected reinfused 
cryopreserv. >20x109/L >îxlÔ9/L 
(days) (days) 
1 yes 15 mo 13.4 2.2 2.0 - 15 
2 yes \k mo 11.2 1.2 1.2 
3 yes 18 mo 6.9 0.5 0.6 
k yes 26 mo 16.3 19.2 12.3 
5 yes 21 mo 7.A 33.2 26.6 
6 yes 24 mo 1»5.2 №.2 44.6 
7 yes 33 mo 11.8 4.8 8.2 
8 yes 1 mo 4.9 NA 7.4 
9 yes 2 mo 7.3 NA 13.3 
10 yes 3 wks 19.1 17.2 16.8 
11 yes 1 wk 10.1 4.0 2.2 
10.1 4.0 2.2 
12 no 7 mo 24.4 20.9 I'*.'» 
13 yes 7 wks 6.8 3.5 9.5 
14 yes 1 mo 14.4 12.7 5.8 
15 yes 6 mo 12.2 4.8 3.4 
16 no 18 mo 7.7 10.9 10.0 
17 yes 25 mo 20.2 10.0 7.6 
29 mo 20.2 10.0 7.6 
18 yes 2 mo 9.5 3.1 6.9 
19 yes 10 mo 14.3 9.5 10.5 
mean ± SD 14.0±8.6 11.6±11.0 10.2±9.8 25.8±11.7 20.0±6.8 
Λ4- not available, NC= nucleated cells, mo= months, wks= weeks, * The number of days before the 
cells increased above the indicated levels, leucoc= leucocytes, thromoc= thrombocytes. 
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Fi$ 1 : Correlation between the number of CFU-GH 
reinfused and the duration of thrombocytopenia 
(9), (correlation coefficient - 0.075) and the 
duration of leukocytopenia (O), (correlation 
coefficient · 0.28). 
The patients nrs 15, 16 and 17 showed a response of 3 weeks, 7 weeks 
and 4 months respectively. All three were heavily treated with 
chemotherapy before they relapsed and had minimal tumor load after 
surgical debulking of the relapsed tumor. In patient nr 18 the high 
dose therapy induced a CR, which could not be obtained with 
conventional combination therapy. This remission lasted only 2 
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months. Patient nr 19, treated in second CR of a Hodgkin's disease is 
without evidence of disease 10+ months. 
No significant correlation was found neither between the number of 
nucleated cells nor the number of CFU-GM reinfused and the duration of 
the aplastic period (fig 1). The mean duration of thrombocytopenia 
was 25 ± 12 days and of the leukocytopenia 20 ± 7 days. 
Two patients with acute leukaemia in relapse died in the aplastic 
phase; one patient (nr 2) in the first week after ABMT due to 
intractable gastro-intestinal hemorrhage, the second patient (nr 1) in 
the fourth week after ABMT after she had become refractory to platelet 
transfusions. She represents the only toxic death due to a delayed 
bone marrow regeneration. The third patient (nr 3) treated with ABMT 
while in relapse of his acute leukaemia died 7 weeks post-ABMT with a 
normocellular bone marrow. Al] these 3 patients received a low number 
of CFU-GM (< 2.104/kg). 
The fact that almost no correlation was found between the number of 
nucleated cells respectively CFU-GM reinfused and the repopulation 
time is also illustrated in patients nrs 11 and 17. They both 
received two consecutive identical courses of bone marrow ablative 
therapy followed by reinfusion of the same number of nucleated cells 
and CFU-GM. In both patients the first period of aplasia was 
complicated by febrile episodes and lasted much longer than the second 
period (table II). 
DISCUSSION 
Since the problem of bone marrow storage was solved and techniques for 
quality control by assessment of bone marrow progenitor cells became 
available, ABMT is an accepted technique to rescue after bone marrow 
ablative regimens. As the experience with ABMT increased, the 
indications for high dose radio-chemotherapy have changed, which is 
illustrated in the described patient groups. In broad outline three 
categories of patients can be distinguished; 
1) The first three patients with acute leukaemia and the first two 
patients with a solid tumor were treated when they still had a large 
tumor load. All three patients with acute leukaemia died in relation 
- 47 -
to the intensive treatment protocol, although two of them attained a 
CR The two patients with adenocarcinoma showed some tumor reduction 
and a temporary delay in tumor progression 
2) The next four patients with acute leukaemia and the next four 
patients with a solid tumor received ABMT after previous reduction of 
the tumor load. The effect of the intensive consolidation course on 
the duration of the CR of acute leukaemia in comparison with 
conventional consolidation protocols cannot be evaluated in this small 
patient group The four patients with a relapse of a solid tumor were 
surgically debulked to nunimalize the tumor load However, despite 
the limited tumor load no long term remission was obtained Tumor 
cell resistance might be responsable for the disappointing results in 
these heavily pre-treated patients This was illustrated by the 
patient with a Ewing sarcoma, showing tumor reduction after a first 
high dose melphalan treatment followed by ABMT. but no response after 
a second, identical course These data suggest that effective 
treatment schemes should be preserved to earlier phases of malignant 
disease 
3) The third categor> consisted of patients in first CR of leukaemia 
with high risk of relapse and a patient with a second CR of a bad risk 
Hodgkin's disease In this group of patients the bone marrow ablative 
therapy can be considered as an intensive consolidation course In 
case of T-ALL removal of residua] leukaemic blast cells from the graft 
was attempted by in vitro incubation of the marrow bith immunotoxins. 
In this approach ABMT was used as a first line treatment. 
The results of bone marrow ablative therapy and ABMT in relapsed 
patients presented in the literature are disappointing (11). Another 
argument not to continue this intensive treatment protocol in patients 
in relapse of acute leukaemia are the data obtained from allogeneic 
bone marrow transplantation m patients treated in relapse of acute 
leukaemia showing a relapse rate of 70%, besides high risk of therapy 
related death (12) 
In small cell lungcancer bone marrow ablative consolidation therapy 
seems to be successful as a first line treatment (13,14). The effect 
of high dose consolidation therapy has also been investigated in 
relapsed neuroblastoma (15), and lymphomas (9), but the definite 
advantage of this approach in comparison with conventional treatment 
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modalities has yet to be given 
The only patient with a defective repopulation of the bone marrow 
received 2.10 CFU-GM/kg. Two patients received a lower number of 
CFU-GM. One of these could not be evaluated because of early death. 
The other patient died with a normocellular bone marrow but he did not 
receive total body irradiation because of his age. All patients 
except one showed complete bone marrow recovery, the shortest 
repopulation time being 13 to 15 days. In some patients recovery was 
delayed, but there was no significant correlation between the number 
of CFU-GM infused and the duration of aplasia. The delayed recovery 
after the first reinfusion in both patients treated twice with the 
same course can be attributed to infectious complications during the 
first treatment. The conclusion seems to be justified that if the 
4 
number of CFU-GM infused is sufficient (> 2.10 /kg), repopulation time 
mainly depends on infectious complications during the period of 
aplasia perhaps aggravated by the use of antibiotics (16). 
The absence of late infectious complications as usually seen after 
allogeneic bone marrow transplantation, may be explained by a rapid 
recovery of the number of T-lymphocytes, OKT-4 cells and OKT-8 
cells. This was observed in a cooperative study, including 4 patients 
of this study (17). 
Bone marrow ablative therapy has proven to be a safe treatment 
modality if combined with ΛΒΜΤ. Based on the experiences from this 
and other studies such very intensive treatment protocols should be 
restricted to cases with minimal tumor load and in an early phase of 
the disease when therapy resistance is negligable. 
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CHAPTER 4 
THE EFFECT OF EXPOSURE TIME AND DRUG CONCENTRATION ON CLONING 
EFFICIENCY AFTER INCUBATION OF HUMAN BONE MARROW WITH CYTOSINE 
ARABINOSIDE 
R Raijmakers, Τ de Witte, Ρ Linssen, J Vessels, С Haanen 
In press: British Journal of Haematology 
SUMMARY 
The effect of different cytosine arabmoside (Ara-C) concentrations 
and exposure times upon clonogenicity of normal bone marrow cells was 
studied One hour incubation, even at the pharmacologically high 
Ara-C concentration of 10 M, was not cytotoxic. Prolonged 
incubation resulted in a tremendous increase in Ara-C cytotoxicity. 
The results show that long term exposure to Ara-C, even at 
pharmacologically very low concentrations, is deleterious for 
clonogenic cells and provide an experimental basis for the reported 
therapeutic efficacy of long term low dose Ara-C administration in 
leukaemia and preleukaemic syndromes 
INTRODUCTION 
Long term low dose Ara-C administration has been reported effective 
for inducing remissions in acute leukaemia and dysmyelopoietic 
syndromes (1,2,3) A dosis of 10-20 mg/sqm is usually given 
subcutaneously every 12 hours for 8 to 28 days This dosage is about 
10 times lower than conventional intravenous dosages, but administered 
for much longer periods of time Ara-C plasma levels were detectable 
in serura for 30-60 minutes following subcutaneous injection, the 
detection limit being 1 2x10* M (3). 
Although low dose Ara-C has been supposed to induce differentiation of 
leukaemic blast cells, bone marrow hypoplasia has been observed 
repeatedly after such a course, suggesting a cytotoxic effect (4) In 
this study in vitro cytotoxicity of Ara-C to clonogenic cells has been 
determined at high and low drug concentrations and after short and 
long incubation times. The inactivation of the drug by deammation 
was measured under various conditions, in order to evaluate the 
effective Ara-C exposure The results show a very strong 
time-dependent cytotoxicity of Ara-C providing an experimental basis 
for the observed cytotoxic effect of long term administration of low 
dose Ara-C in clinical experience 
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MATERIALS AND METHODS 
In vitro bone marrow processing Normal bone marrow from patients 
undergoing coronary bypass surgery was used for this study The bulk 
of red cells was removed from the aspirate by isopycnic sedimentation 
centrifugation as described earlier (5) In short: The aspirated 
bone marrow was collected in buffered acid citrate dextrose (pH 7 4) 
and washed in Ca/Mg-free Hanks' balanced salt solution (HBSS) for 
removal of plasma and fat. The pellet was resuspended in HBSS, 
supplemented with 5°,, fetal calf serum (FCS) 150-200.10 cells in 35 
ml suspension are layered upon 15 ml Percoli (specific density 1 085 
g/ml, pH 6.6, osmolality 300 mosm/kgi and centnfuged at 500 g, 18°C, 
for 20 minutes. The interphase cells were washed twice in HBSS and 
resuspended in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with 20% FCS The number of nucleated cells is determined with a 
Coulter Counter ZF (Coulter Electronics LTD., Dunstable Beds, UK) 
Granulocyte-Macrophage colony forming assay (CFL'-GM) • All cultures 
were performed in 35 mm Petri dishes (Costar) in duplicate. Two ml 
cell suspension containing 10 cells/ml in DMEM, supplemented with 20°<, 
FCS, 5°o (v/v) colony stimulating factor and 0.3°„ (w/v) bacto-agar 
(Difco), was pipetted per dish. The colony stimulating factor used 
was Human Placenta Conditioned Medium (HPCM), derived from human 
placenta conditioned in the presence of endotoxin as described by 
Verma et al (6). 
The cultures were incubated at 370C in a fully humidified atmosphere 
of 5°o CO, in air. After 10-12 days cell aggregates consisting of 40 
cells or more were scored as colonies. 
Ara-C solutions All dilutions of Ara-C were made freshly from a 
frozen stock solution of 1000 nmol/ml preservative free Cytosar 
(Upjohn), that has been checked for concentration and purity by High 
Pressure Liquid Chromatography (HPLC) 
Continuous incubation with Ara-C. The dose response curves in case of 
continuous incubation to Ara-C were obtained using one bone marrow 
cell suspension (10 cells/ml), prepared as described under bone 
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marrow processing and made up in complete medium with agar (see 
CFt-GM-assay). Two mis were brought into Petri dishes containing 100 
μΐ Ara-C dilution at 2.1 times the final incubation concentration 
After thorough mixing the plates were cultured for 10 days. 
Incubation with Ara-C. Ara-C incubations were performed at two 
different cell concentrations (10 cells/ml and 10 cells/ml) and for 
different incubation times (1, 24, 48, 72 and 120 hrs) in DMEM, 
supplemented with 20^, FCS and 5°» HPCM (v/v) In each experiment one 
single cell suspension was prepared for all different drug 
concentrations and incubation times, filled out in culture tubes and 
pre-incubated for one hour (100oo humidified atmosphere, 5^ . CO in air, 
37 0C). Subsequently 100 ul Ara-C in an appropriate concentration was 
added and the incubation started 
To stop the incubation with Ara-C the suspension was diluted 5-fold 
with HBSS (4I,C) and centnfuged (10 min, 500g, 4IIC) . Subsequently the 
pellet was washed twice in HBSS. The final pellet was resuspended, 
counted and made up to a concentration of 10 cells/ml in complete 
culture medium with agar and plated 
Measurement of Ara-C and Ara-L' by HPLC. HPLC measurements were 
performed as described by Linssen et al (7) To stop deamination 20 
ul tetrahydrouridine (1 ug/ml) was added. The coll suspensions were 
centnfuged (10 m m , 500 g, 4°C) and the supernatant fluids collected 
for measurement of Ara-C and Ara-U. 
In order to enable measurements in semi-solid cultures, the agar was 
made soluble by addition of 400 ul perchloric acid (PCA, 1 M) After 
thorough mixing, 1 25 ml of the suspension was pipetted in a test 
tube, the excess of PCA precipitated with 200 ul 4 Μ К HPO, and 
removed by centnfugation. Ara-C and Ara-U content were measured in 
the supernatant fluids. 
RESULTS 
One hour incubation of bone marrow cells at pharmacologically high 
concentrations of Ara-C (up to 10 M) did not induce even a 50% 
inhibition of colony growth for CFU-GM, stimulated to proliferate by 
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Fig 1. Dose response curves aitar 1 hour incubation ( ) and 
continuous exposure (Ш) to Ara-C m vitro. The number of 
colonies are presented as percentage of colonies obtained m two 
duplicate control cultures. 
Time dependent cytotoxicity became more obvious when the inhibitory 
concentration Ara-C reducing the number of colonies to 50°o of the 
control culture (D 50) was determined at increasing incubation times 
(fig 2). After 24 hours incubation of 10 cells/ml, an D 50 was noted 
at (1.7 + 0.7)-'-10" M (n=5). The D 50 became more than 2 logs lower, 
-8 (0.8 ± 0.4)"'"10 M (n=5), when the incubation time was prolonged up to 
5 days. Continuous incubation (10 days) resulted in an D 50 of 
-8 (0.65 ± 0.4)-'-10 M (n=12), which is not essentially different 
compared to the D 50 found after 5 days incubation Time-dependent 
cytotoxicity became less obvious when the incubations were done with 
10 cells/ml (fig 2) the D 50 after 24 hours incubation of 
(1.4 ± 0.9)'·-1θ"6 M (n=10) decreased to (2.0 ± 1 1)-·-1θ"7 M (n=4) after 
5 days incubation. The results of incubations at 10 cells/ml for 
more than 5 days were considered unreliable, because the culture 
medium became exhausted at that cell concentration. 
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Fig 2: D 50 values for CFU-Gfl after different 
exposure times at 10 cellslml (0) and 106 
eel Is/ml (Ш). D 50 is defined as the dose Ara-C 
which gives a 50% inhibition of the number of 
colonies compared to the control cultures. Data 
of 10 days exposure at 10 cells/ml are not given, 
as at that cell concentration the culture medium 
became exhausted. 
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Fig 3: Deammation of Ara-C after incubation of 
Both cells at 10 cells/ml and 10 cells/ml 
Ara-C CO) and Ara-U СШ) concentrations are given 
for an initial Ara-C concentration of 10 and 
lu'6 M 
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Fig 4: Deamination of Ara-C in liquid (%) and semi-solid 
medium (Ш) at a cell concentration of 10 cells/ml and an 
Initial Ara-C concentration of 10 H. Ara-U in liquid (O) and 
semi-sol id medium (O) 
The effect of Ara-C deamination at different cell concentrations. 
Because Ara-C is deaminated in vitro the Ara-C concentration decreases 
during incubation, reducing the exposure effectivity. For that reason 
we measured the deamination product, uracil arabinoside (Ara-U). At a 
cell concentration of 10 cells/ml the rate of deamination appeared 
much faster than at 10 cells/ml. After 5 days incubation of 10 
cells/ml no Ara-C could be detected in the supernatant while 
incubation with 10 cells/ml caused in that period an Ara-C reduction 
3 
of 65?ó (fig 3). After 5 days incubation of 10 cells/ml about 90% of 
the Ara-C appeared still present (data not shown). The rate of 
deamination at the 2 different cell concentrations was similar for 
10 and 10 M Ara-C. Comparison of the deamination in liquid and 
semi-solid medium showed that the rate of deamination was comparable 
(fig 4). This excludes interference of agar with Ara-C deamination. 
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Deamination could be attributed to the cells, since Ara-C 
concentration did not decrease during 10 days incubation in cell free 
medium. 
DISCUSSION 
Time-dependent cytotoxicity of an S-phase specific drug like Ara-C can 
be expected, because the cytotoxic effect is limited to the fraction 
of clonogenic cells that traverses the sensitive phase. The escape of 
CFU-GM after 1 hour incubation, even at very high Ara-C 
concentrations, can be explained from a very limited number of cycling 
progenitor cells. This phenomenon has been described as "cell kinetic 
resistance" (8). 
However, apart from cell kinetics a strongly time-dependent 
cytotoxicity is found. After one hour exposure we observed no effect 
of Ara-C on cloning efficiency of CFU-GM, although about 30% of the 
CFU-GM are traversing the sensitive phase of the cell cycle, as 
measured by 3H-thymidine suicide index (8). After 24 hours incubation 
a 50% inhibition of clonogenicity can be obtained. The D 50 decreased 
more than 2 logs after prolonging the incubation time from 24 hours to 
5 days. Diminished Ara-C cytotoxicity after 5 days incubation of 10 
instead of 10 cells/ml appears to be related to the increased rate of 
deamination of the drug, decreasing the effective Ara-C exposure. 
These observations provide arguments for a strongly time-dependent 
Ara-C cytotoxicity. 
-9 
A lower D 50 (under 6.10 M) is expected to be obtained when 
deamination is further reduced by incubating at cell concentrations 
below 10 cells/ml. When the Ara-C concentration is kept constant the 
lowest D 50 could be expected. 
The concentrations of Ara-C that are cytotoxic after long term 
incubation are much below the plasma levels obtained during long term 
low dose treatment by subcutaneous injection of 20 mg/m2 Ara-C twice 
daily (3). The time-dependent cytotoxicity found in this study, using 
normal CFU-GM stimulated to proliferate by HPCM, did not increase much 
after 5 days incubation. In vivo, part of the clonogenic cells will 
be out of cycle or proliferate at a low rate. This may explain the 
need to continue low dose Ara-C treatment for several weeks before it 
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shows clinical efficacy. 
Although the clinical experience of the favourable effect of long term 
treatment with low dose Ara-C may be widely different from the 
experimental situation, our in vitro data provide an experimental 
basis for the mechanism of action. Ara-C becomes cytotoxic at very 
low concentrations when the effective exposure time is long enough. 
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CHAPTER 5 
CELLULAR ADRIAMYCIN CONCENTRATIONS AFTER PUSH INJECTION OR CONTINUOUS 
INFUSION AND THE CYTOTOXIC EFFECT ON HUMAN BONE MARROW CLONOGENIC 
CELLS 
R Raijmakers, Ρ Speth, Τ de Witte, Ρ Linssen, J Wessels, С Haanen 
submitted to: Experimental Hematology 
SUMMARY 
Adriamycin (ADM) accumulates intracellularly very rapidly and to 
concentrations far above the plasma levels After a bolus injection 
the cellular ADM concentration increases rapidly, simultaneously with 
the increasing plasma concentration, but in contrast to the rapid and 
almost complete disappearance of ADM from the plasma, the cellular ADM 
concentration remains at an almost steady level If the same dose was 
administered as a 4 or 24 hours continuous infusion, the plasma levels 
were significantly lower, but the cellular accumulation gradually 
reached the same level as obtained after a bolus injection 
The cellular ADM course after bolus injection and continuous infusion 
was simulated in vitro by short, intermediate and long term exposure 
of human bone marrow cells, during different periods of time The 
cytotoxic effects of these different modalities of ADM exposure were 
measured by means of clonogenic assays 
The achieved cellular ADM concentrations correlated with the cytotoxic 
effect, irrespective of the fact whether they were attained after a 
short exposure to high or a long term exposure to low ADM 
concentrations The in vitro results together with the similarity of 
the cellular ADM disappearance-rate in vitro and in vivo justify the 
conclusion that the cytotoxic effect of a certain dose applied as a 
continuous infusion is comparable to the effect of administration of 
the same dose as a bolus injection Undesirable side-effects, such as 
cardiotoxicity, nausea and vomiting are much more pronounced after a 
bolus injection Therefore a constant-rate infusion of ADM seems more 
appropriate in order to obtain the optimal cytotoxic effect with the 
least possible undesired side-effects 
INTRODUCTION 
Adriamycin (ADM) is usually administered as a bolus injection 
However, the same dose may be applied as a continuous infusion, 
lasting for several hours or days Prolonged administration has the 
advantage of avoiding high peak plasma concentrations (1), thus 
reducing undesirable side-effects such as cardiotoxicity, nausea and 
vomiting (2) The cumulative dose of 550 mg/m2 ADM given as bolus 
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injection may safely be increased to much higher cumulative doses when 
the drug is administered by means of continuous infusion (2,3) 
Therapeutic effects of bolus injection compared to continuous infusion 
are equivalent in case of leukaemia (4) and breast cancer (5). 
After bolus injection plasma ADM shows a pattern quite different from 
the one after continuous infusion, after bolus injection short-lasting 
extremely high ADM concentrations are measured, while during 
continuous infusion plasma drug-levels remain much lower (1) In this 
study the implications of cellular ADM concentrations on clonogemcity 
are investigated for different ways of administration The cellular 
concentrations, in contrast with the plasma concentrations, determine 
the cytotoxic effect 
The cellular ADM courses after both bolus injection and continuous 
infusion, were simulated by in vitro short, intermediate and 
long-lasting exposure. This simulation offered the opportunity to 
correlate cellular ADM concentrations with the cytotoxic effect on 
clonogenic cells 
MATERIALS AND METHODS 
Drugs ADM was obtained from Laboratoire Roger Bellon S A (Neuilly 
sur Seine, France) The ADM concentrations in the stock solutions 
were checked by high pressure liquid chromatography (HPLC) 
Patients. Patients with leukaemia were treated in accordance with a 
protocol consisting of ADM (30mg/m2, day 1,2,3), Vincristine (1 mg/m2, 
day 2) and cytosine arabinoside (100 mg/in2, as a continuous infusion 
in combination with a bolus injection of 50 rag/m2, twice a day, day 1 
to 7). ADM was administered as bolus injection or continuous 
infusion 
Bone Marrow. Normal bone marrow was obtained from cardiac surgery 
patients (Dept. Cardiac Surgery, head· Prof. Dr. L.K Lacquet). 
The bulk of red cells was removed from the bone marrow aspirate by 
isopycnic density centnfugation (6). In brief; the aspirate was 
collected in acid citrate dextrose (ACD-A, pH 7.4) and after addition 
of isotonic glucose phosphate buffer (buffer) centrifugated to remove 
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plasma and fat. The pellet was resuspended in 35 ml buffer 
supplemented with 5\ fetal calf serum (FCS), layered on 15 ml of 
Percoli (density 1 085 g/ml, pH 7 4, 300 mosm/kg) and centrifugated 
(500 g, 18°C) for 20 minutes. Cells at the interphase were washed 
twice with buffer and resupended in Modified Eagle's Medium (MEM) 
supplemented with 10% FCS The number of nucleated cells was 
determined electronically (Coulter Counter ZF, Coulter Electronics, 
Bedfordshire, UK). 
ADM Incubations. In each experiment, individual marrow suspensions at 
a concentration of 10 cells/ml were aliquoted in 50 ml polypropylene 
tubes (Greiner, FRG) and pre-incubated at 3 7 ^ for 1 hour Next, ADM 
was added and the suspensions were incubated for 5 minutes, 2 hours 
and 24 hours respectively. Following the incubation, samples were 
taken for flow cytometric determination of cellular anthracycline 
concentrations. The residual cell suspensions were diluted twice with 
cold buffer (O'C) to stop further drug uptake and centrifugated (900 
g, 0CC, 5 minutes). After a second washing procedure the pellet was 
resuspended in culture medium and another sample was taken for 
analysis of cellular anthracycline concentrations. Part of the cell 
suspension was plated in semi-solid medium to assay for clonogenic 
potential. Part of the cell suspension was diluted in liquid medium 
for further monitoring of cellular ADM concentrations. 
Granulocyte-macrophage colony forming cells (CFU-GM) assay All 
cultures were performed in duplicate in 35 mm Petri dishes (Costar, 
Cambridge, Mass.) as described previously (6) In brief; each dish 
contained 2 ml of a cell suspension (10 cells/ml) in Dulbecco's 
Modified Eagle's medium (DMEM) supplemented with 20°„ FCS, 5% (v/v) 
colony stimulating activity (CSA) from human placental conditioned 
medium (HPCM) , as described by Verma et al (7) and 0.3 ?» (w/v) bacto 
agar (Difco, Detroit, Mich.) The cultures were incubated at ЗТ'С in 
a fully humidified atmosphere of S"» CO,, in air. After 10-12 days, 
cell aggregates consisting of 40 cells or more were scored as 
colonies. 
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Preparation of cell samples for flow cytometry (FCM). Samples for FCM 
were cooled on ice and subsequently ccntrifugated (5 min, 00C, 900 g). 
The pellet was resuspended in 1.5 ml cold lysis buffer (8.29 g NH.Cl, 
37 mg К EDTA and 1 g KHCO per liter, pH 7.3) to lyse erythrocytes and 
normoblasts (8). The tubes were kept on ice and regularly tilted. 
After centrifugation (5 min, 0°C, 900 g) the supernatant was 
discarded. The cells were resuspended in cold phosphate-buffered 
saline (PBS) at a concentration of about 3.10 cells/ml and kept on 
ice until FCM analysis for cellular ADM concentration (8). Storage at 
U°C showed no loss of fluorescence. 
Light scatter and cellular fluorescence measurement by FCM. FCM 
measurement was performed on a System 50H Cytofluorograph (Ortho 
Diagnostic Systems Inc., Westwood, MA) equipped with a 5-W argon laser 
(164-05, Spectra Physics, Mountainview, CA) excitating at 488 nm with 
an intensity of 0.5 W (8). Fluorescence was measured with a barrier 
filter OG550 (Melles Griot Optical Industries, Costa Mesa, CA). The 
combination of forward light scatter (FLS) and perpendicular light 
scatter (PLS) was used to discriminate the major white cell 
subpopulations and cell debris. From each sample at least 12,000 
cells were analysed at a flowrate of 1,000 cells/s. 
Data of FLS, PLS and fluorescence per cell were measured in area mode, 
stored in list mode and analysed on a PDP 11/34 computer (Digital 
Electronic Compaiiy, Maynard, MA). Cellular ADM concentrations are 
expressed in arbitrary fluorescence units/cell (FU/cell), representing 
the mean fluorescence of an investigated cell population. All 
fluorescence data presented are corrected for autofluorescence by 
subtracting the blank value. As described previously (8), the 
arbitrary fluorescence units showed a significant correlation with the 
cellular ADM concentrations determined by HPLC (see below). 
Measurement of plasma and cellular ADM by HPLC. The straight phase 
HPLC method described by Baurain et al (9) was used with minor 
modifications. In brief: 10 cells were sonicated for 15 s at 75 W 
with a MSE Soniprep 150 Ultrasonic Disintegrator (MSE Scientific 
Instruments, Crowley, UK). To 250 vl cell suspension or 500 ill plasma 
3 ml chloroform/methanol 9:1 (v/v) was added, followed by 100 μΐ tris 
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buffer (1 M, pH 8.7) containing daunomycin as internal standard. 
After two extractions with chloroform/methanol 9:1 (v/v), the 
chloroform phase was collected and evaporated. The residue was 
dissolved in 750 ui chloroform/methanol, with addition of 50 ul tris 
buffer. A 500 ul sample was injected into the column (Lichrosorb 
5Si60 column 100 χ 3.0 mm ID). The column was eluted with chloroform, 
methanol, glacial acetic acid, and 0.3 mM MgCl (720:210:40:30 v/v) 
under addition of desipramine 10 mg/1 (kindly supplied by Ciba Geigy, 
Basel, Switzerland) to decrease adsorption effects of anthracyclines 
to the tubings. Detection was carried out with a fluorometer 
(λ-excitation at 488 nm, λ-emission above 550 nm)(FS 970 L.S. 
Fluorometer, Schoeffel Inst. Corp, Ramsey, NJ). Quantitation of the 
drug concentration was achieved by measurement of the peak height 
ratio of drug and internal standard and calculated from a calibration 
curve of peak height versus concentration. The detection limit of ADM 
and metabolites was determined at 1 ng/ml. The within-day precision 
of the method (n=17) was 7.0%. 
RESULTS 
In vivo plasma and cellular ADM concentration courses. A bolus 
injection of ADM (30 mg/m2) produced a steep rise of the plasma ADM 
concentration to over 1000 pg/ml. The plasma disappearance curve of 
ADM showed a biphasic pattern. During the first phase the plasma 
concentration decreased rapidly, with a t of 9 minutes, followed by 
a further decrease of plasma ADM at a considerably slower rate with a 
t .. of 50 hours. 
Cellular accumulation of ADM followed the plasma levels almost 
instantaneously and reached concentrations of about 5 times the peak 
plasma values as indicated in figure 1. The cellular ADM 
disappearance curves were also biphasic. A rapid phase of very short 
duration, with a t. .0 of 4 minutes was followed by a phase with a slow 
disappearance rate with a t of 100 hours. The discongruency 
between plasma and cellular ADM elimination resulted in cellular ADM 
concentrations, that were 3 logs higher than the plasma 
concentrations. 
When the same amount of ADM was administered as a constant rate 
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Fig 1: Plasma and cellular pharmacokinetics of 
ADH 30 mg/mZ administered respectively as push 
injection, 4 and 24 hours continuous infusion 
Arrows indicate the duration of administration. 
(X)=cellular and (Щ)=plasma ADH concentrations, 
(O l^plasma adriamycmol concentrations. 
infusion of 4 hours, the maximal plasma concentration reached 60-80 
ng/ml At the end of the infusion the plasma-disappearance curves 
showed a biphasic pattern at a lower level Essentially they were not 
different from the disappearance-curves after bolus injection. At the 
end of the infusion the cellular ADM concentration curves showed a 
small decrease. Thereafter they remained at a concentration level, 3 
logs higher than the plasma values, for at least 36 hours (t of 
more than 100 hours) 
Prolonging the constant-rate infusion to 24 hours resulted in even 
lower maximal plasma levels (20 ng/ml) and a slow, but continuously 
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cellular accumulation of the drug. The cellular ADM disappearance 
after termination of the infusion showed a monophasic pattern (t.... of 
100 hours). In all three modes of drug administration one hour after 
the plasma ADM had disappeared, almost identical cellular drug 
concentrations were attained irrespective of the different patterns of 
administration. 
cellular fluorescence (Fu/cell) 
a 
3 000 
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4 6 θ 10 
adriamycm ( jug/ml ) 
Fig 2: The eolation between the exposure concentrations and the 
cellular ADtl concentrations at the end of the incubation Ca) and 
after reincubation of the cells (b). This relation was 
determined after 5 min=(O ) , 2 hours=(0 ) and 24 hours=(% ) ADtl 
incubation. 
Course of in vitro cellular ADM concentrations. Incubation of human 
haematopoietic cells for 5 min, 2 and 24 hours with increasing ADM 
concentrations resulted in cellular concentrations wich were linearly 
related with the ADM concentrations in the incubation medium (fig 2a). 
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After reincubation in ADM-free medium cellular ADM concentrations 
still showed a linear relationship with the initial ADM incubation 
concentrations. However, the cellular ADM concentrations diminished 
especially after 5 min incubation (87-91%) and to a lesser extent 
after 2 hours (27-51%) and 24 hours (12-23°,) incubation respectively. 
The concentration-courses after these 3 incubation times (fig 3) are 
comparable with the concentration-courses after in vivo push injection 
and short and long-lasting ADM infusions (fig 1 ) . 
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Fig 3: Cellular ABM concentrations (in FU/cell) 
attained by m vitro exposure of bone marrow cells 
during 5 mm (a), Ζ (b) and 24 (c) hours. Arrows 
indicate the incubation times and concentrations 
The incubation concentrations chosen all resulted 
m a similar cytotoxic effect. 
Effect of ADM incubation on clonogenicity. The concentration-response 
curves for all 3 exposure times are plotted m figure k. A 50« 
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inhibition of clonogenic cells (D 50) was achieved by 5 minutes 
exposure to a concentration of 2 2 ug/ml ADM Prolonged exposure 
showed increased cytotoxicity The D 50 became 0 35 and 0 05 pg/ml 
after 2 and 24 hours respectively An even lower D 50 of 0 0056 
yg/ml, was achieved after continuous exposure when ADM was added to 
the semi-solid culture medium 
Iff 10' 10"' 10w 10' 10' 
adriamyan exposure concentration (jug/ml) 
Fig 4• Inhibition of clonogenic cells at increasing ADH 
concentrations for different incubation times (·\·)= 5 mm 
incubation, (X)= 2 hours incubation, (Ç>)=24 hours incubation, 
(0)= continuous exposure The relative number of colonies is 
expressed as percentage of two duplicate control cultures for 
each incubation time (n=4) 
Figure 5 shows the attained cellular ADM concentrations plotted 
against the inhibition of the clonogenic cells. The inhibition 
of clonogenic cells was directly related to the cellular ADM 
concentrations attained after reincubation, not dependent of the 
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incubation time and not influenced by a short-lasting ADM 
peak-concentration, attained after short incubations 
100 
cellular adnamycin concentration ( F u / c e l l ) 
Fig 5 Inhibition of clonogemcity plotted against cellular ADM 
concentrations (expressed as FU/cell) measured after 
remcubation. (-\-)=5 mm, (X)=2 and (0)=24 hours incubation. 
The relative number of colonics is expressed as percentage of two 
duplicate control cultures for each incubation time (n=4) 
DISCUSSION 
In vivo, after administration of the same amount of ADM as a bolus 
injection, a short or a long term infusion, different cellular ADM 
concentration-courses were observed 
As shown in this study the cellular ADM concentration-course after 
short- or long-lasting ADM administration may be simulatfd in vitro by 
varying exposure-times and drug-concentrations. After a short-lasting 
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exposure, ADM accumulated intracellularly very rapidly to values far 
above the plasma concentration. However, the shorter the incubation 
period, the more of this cellular ADM was lost after reincubation in 
drug-free medium. Apparently, part of the ADM was loosely bound, and 
part was bound more tightly. The mechanism behind this observation is 
speculative. It may be explained by a very fast cytoplasmatic 
accumulation followed by a time-dependent slow intercalation into the 
DNA (10). Prolonging the in vivo exposure-time using the same dose, 
resulted in lower plasma levels and a slower cellular accumulation, 
but the quantity of tightly bound cellular ADM was the same. 
Nguyen-Ngoc et al (11) and Andersson et al (12) stressed the 
importance of the cellular peak-concentrations of anthracyclines with 
respect to the cytotoxic effect. Both authors based their conclusions 
on in vitro experiments, in which the product of concentration and 
time had to be increased with the exposure time in order to obtain the 
same cytotoxic effect. Nguyen-Ngoc et al based their dose 
calculations on the ADM concentrations at the start of the exposure. 
They did not check changes in medium concentrations, which tend to 
decrease during incubation (13) nor did they measure cellular ADM 
concentrations. Andersson et al used for their calculations the 
cellular daunorubicin concentration attained after the cells were 
reincubated in drug-free medium. Thus cellular drug loss during the 
washing-step is neglected. In case of daunorubicin the weakly bound 
fraction is even greater than in case of ADM (10). Especially after 
short exposure with high daunorubicin concentrations their calculated 
dosis are expected to be too low. 
Bailey-Wood et al (14) concluded from their results that the high 
concentrations of drug present in the plasma for short periods of time 
following intravenous infusion were only weakly cytotoxic. However, 
we observed that a short-lasting exposure can be just as cytotoxic as 
a long-lasting exposure provided that the cellular ADM concentrations 
attained after the disappearance of plasma concentrations are in the 
same order of magnitude. 
Measuring the cellular ADM concentration-courses after push-injection 
and short- and long-lasting in vivo administration and simulating 
these cellular ADM-course in vitro, showed that the cytotoxic effect 
of ADM varies with changes in the relatively tightly bound cellular 
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ADM fraction The cytotoxic effect is not enlarged by the 
short-lasting ADM peak-concentrations attained after push-injections. 
These peak-concentrations are equally cytotoxic and they have the 
disadvantage of increased cardiac toxicity and acute toxicity, such as 
nausea and vomiting. 
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CHAPTER 6 
IN VITRO DIFFERENTIAL SENSITIVITY OF NORMAL HEMATOPOIETIC AND MOLT-4 
CELLS TO CYTOSINE ARABINOSIDE 
R Raijmakers, Τ de Witte, J Boezeman, J Wessels, С Haanen 
submitted for publication in: Leukaemia Research 
SUMMARY 
Schemes for therapeutic cytosme arabinoside (Ara-C) administration in 
leukaemia vary from long-lasting infusions of low dosages to 
short-lasting high concentrations Most schemes showed to be 
effective and no scheme proved to be essentially superior 
In this study the in vitro effect of exposure time on the differential 
kill of normal myeloid progenitorcells (CFb-GM) and a leukaemic 
cell-line (Molt-4) uas investigated It was observed that the 
cytotoxic effect of short-lasting (one hour) Ara-C exposure on both 
cell types was limited Ara-C cytotoxicity increased up to 100 times 
by prolonging the exposure time from one hour to several days 
Simultaneously differential sensitivity increased, with an optimum at 
72 hours 
Our results suggest that differential sensitivity of normal and 
malignant clonogenic cells to Ara-C will be most pronounced after 
long-lasting exposure with a certain optimum The optimal exposure 
time depends on the cell type 
It is shown m this model that selective removal of leukaemic 
clonogenic cells with Aia-C is possible, uithout affecting normal 
clonogenic cells 
INTRODUCTION 
Treatment modalities with cytosme arabinoside (Ara-C) include high, 
conventional and low dose schemes High dose Ara-C (1000-3000 
mg/m2/dose) is usually administered as a one or two hours infusion 
twice daily for 4-6 days The conventional dose Ara-C (100-200 
mg/m2/day) is given over 24 hours during 7-10 days, whereas the low 
dose Ara-C (10-20 mg/m2) is administered for 2-3 weeks, twice daily 
subcutaneously or as continuous intravenous infusion 
In a previous paper we reported the effects of variations in exposure 
times and Ara-C concentrations on the in vitro cloning efficiency of 
human bone marrow cells (4) It appeared that Ara-C cytotoxicity was 
almost absent after one hour exposure, even at the pharmacologically 
very high concentration of 10 M, whereas a complete inhibition of 
clonogenicity was obtained after 24 hours exposure at 10 M. 
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Prolonging the exposure time to 3, 5, or 10 days resulted in a further 
increase of Ara-C cytotoxicity; at 10 M Ara-C no CFU-GM were found 
after 10 days exposure. 
The therapeutic applicability of a cytotoxic drug depends on the 
development of dosage schemes that result in differential kill of 
normal and leukaemic clonogenic cells. In this study an experimental 
model was used to investigate, this fundamental question with regard to 
Ara-C. Normal hematopoietic cells were mixed with cells from the 
leukaemic Molt-4 cell-line and after various exposure-times and drug 
concentrations the differential kill was determined in a clonogenic 
assay. The cell-line chosen is spontaneously proliferating, known to 
be Ara-C sensitive and clonogenic in agar. As a reference for 
cytotoxicity to normal hematopoietic clonogenic cells, bone marrow 
CFU-GM were co-cultured (1,2,3). 
MATERIAL AND METHODS 
Human bone marrow collection. Normal bone marrow from patients 
undergoing cardiac surgery was aspirated from the sternal bone. The 
bulk of red cells was removed from the aspirate by isopycnic density 
centrifugation through a Percoli cushion (density 1.085 g/ml), as 
described elsewhere (5). 
Molt-4 cell line. The Molt-4 cell line was established by Minowada et 
al (6) The cells were growing in RPMI 1640, containing 10% PCS and 
antibiotics (100 U/ml penicillin and 100 ug/ml streptomycin). They 
were maintained in a suspension culture at 370C in a humidified 
atmosphere of 5?i CO in air, and in exponential growth by subculturing 
every 2-3 days. The cultures were started with 0.25x10 cells/ml and 
experiments were made when the cells arrived at a density of 
0.5-1.0x10 cells/ml. The number of cells in S-phase was between 30 
and 40%. 
Clonogenic assay for CFU-GM and Molt-4. All clonogenic assays were 
performed in duplicate in 35 mm Petri dishes (Costar, Cambridge, 
Mass.) as described earlier (5). Briefly, each dish contained 2 ml of 
3 5 
a cell suspension consisting of 10 Molt-4 cells and 10 bone marrow 
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cells per ml Dulbecco's modified Eagle's medium (DMEM), supplemented 
with 20% FCS, 5% (v/v) colony stimulating activity (CSA) from human 
placental conditioned medium (HPCM) as described by Verme et al (7) 
and 0.3% (w/v) bacto-agar (Difco, Detroit, Mich.)· The cultures were 
incubated at 370C in a fully humidified atmosphere of 5% CO in air. 
After 10-12 days, cell aggregates consisting of 40 or more cells were 
scored as colonies. The CFU-GM colonies were loosely configurated, 
whereas Molt-4 cells formed compact round aggregates. Both types of 
colonies are easily distinguishable and were scored separately. 
Ara-C incubations. All dilutions of Ara-C were made in DMEM just 
-3 
prior to use from a frozen stock solution of 10 M preservative free 
Cytosar (Upjohn, Kalamazoo, Mich.). The drug was checked for 
concentration, purity and stability by means of high pressure liquid 
chromatography (8). 
In each experiment individual marrow cell suspensions (10 cells/ml) 
3 
mixed with Mo]t-4 cells (10 cells/ml) were aliquoted, 5 ml in 15 ml 
culturing tubes (Falcon, Becton and Dickinson, Paramus, NY). After 
pre-incubation of the cell suspension for one hour (100% humidified 
atmosphere, 5% C0_ in air, 370C) 0.1 ml of Ara-C was added at varying 
concentrations. Subsequently the suspensions were incubated for 1, 
24, 72 and 120 hours. At the end of the incubation the 5 ml 
cell-suspension was diluted 2-fold with Hank balanced salt solution 
(HBSS) (4°C) to stop further Ara-C incorporation and metabolisation 
and the cells washed 3 times in HBBS by centrifugation (10 min, 500 g, 
4 CC). The final pellet was resuspended and cultured in complete 
medium with agar as described above. 
Definitions and curve fitting. The Ara-C concentrations resulting in 
a 90% inhibition of the number of clonogenic cells were determined 
from the concentration-response curves. These curves were fitted, 
using a model described by the formula: 
This function contains three features; (a) represents the maximal 
plating efficiency (= 100%), (b) represents the concentration at which 
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Inhibition has become 70?;, (с) represents the slope of the downward 
leg of the curve. The model was fitted according to the Gauss-Newton 
regression procedure with use of least square criteria (9). 
RESULTS 
One hour exposure of the mixture of Molt-4 cells and bone marrow cells 
to Ara-C showed a limited reduction in both types of colonies: the 
maximal reduction obtained at the pharmacologically very high Ara-C 
concentration of ίο" M was 39% of the CFU-GM and 80?» of the Molt-4 
colonies (n=4) (fig 1). 
Survival (7o) 
100 
1 0 - 1h 
10" 10 
ι 
- 8 10" 
— ι 1 Γ-
10"6 Ю"5 IO"4 
Ara-С concentration ( M ) 
Fig 1 : Dose-response curve after J hour Ara-C exposure. (O )=ttolt-4 
colonies, (Ώ)=Βοηβ marrow CFU-GM, ( • )=Bone marron CFU-GH control 
curve (bone marrow cells not mixed with ttolt-4 cells)(n=4). 
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Fig 2: Dose-response curves after 24 (2a), 72 
(2b) and 120 (2c) hours Ara-C exposure. 
( 0)=!iolt-4 colonies and (Ώ )=CFU-Gtl in a mixture 
of bone marrow cells and llolt-4 cells. 
(M)=CFU-GH control curve (non-mixed bone 
marrow). D 90=Ara-C concentration resulting in 
90% kill (n=4). 
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Further increase of Ara-C concentration to 10 M did hardly suppress 
more clonogenic cells The differential kill of the normal 
hematopoietic and Molt-4 clonogenic cells was limited, the kill of 
Molt-4 cells was maximally 2 times higher under these conditions 
After 24 hours Ara-C exposure the reduction of both clonogenic cell 
types was 2 logs, obtained at Ara-C concentration of 2 10 M for the 
Molt-4 cells and 3 ΙΟ - 4 M for the CFU-GM (fig 2a) Obviously Molt-4 
cells are much more sensitive to Ara-C, 90o„ suppression of Molt-4 
colonies was obtained at ( 0 3 + 0 06) 10* M and of CFU-GM at 
(15 ± 5 6)"10" M Ara-C (n=4) This means a difference m Ara-C 
sensitivity up to 50 times (Table I) 
Table I Differential sensitivity at the 90^, inhibitory 
level for both Molt-4 cells and CFU-GM after 24, 72 and 
120 hours exposure Differential sensitivity expressed 
as the ratio between the cytotoxic Ara-C concentrations, 
resulting in 90% inhibition of CFU-GM and Molt-4 
exposure time (hours) 
24 72 120 
50 75 30 
In the control cultures without Ara-C and at low Ara-C concentrations 
a suppression of CFL-GM was observed when the number of Molt-4 
colonies was high (fig 2a) This growth suppression is apparently 
caused by a humoral factor produced by the Molt-4 cells This could 
be verified by addition of the supernatant from liquid Molt-4 cell 
cultures, filtered through 0 22 ym millipore filters, to the cultunng 
medium, resulting in a concentration-dependent suppression of CFU-GM 
The longer the exposure time, the lower the cytotoxic Ara-C 
concentrations After 72 hours Ara-C exposure 90 % kill of both 
Molt-4 cells and CFU-GM was obtained at respectively 
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(О 44 ± О 33) IO"7 and (32 4 ± 3 9),-lo"7 M Ara-C (n=4) (fig 2b) 
Lengthening of the exposure time up to 120 hrs resulted in a further 
increase of Ara-C cytotoxicity, 90 % kill of Molt-4 cells and of 
CFU-GM was obtained at respectively (0 17 ± 0 08) ίο" M and 
(5 2 ± 1 6) 10"7 M (n=4) (fig 2c) 
The differential sensitivity calculated from the 90л> inhibitory Ara-C 
concentrations increased from 50 times after 24 hours exposure to 75 
times after 72 hours exposure and subsequently decreased to 30 times 
difference in Ara-C concentration (table I) after 120 hours So, in 
contrast to the Ara-C sensitivity increasing with the exposure time 
the differential sensitivity at the 90°,, inhibition level showed an 
optimum after 72 hours 
DISCUSSION 
Cytotoxicity of Ara-C to clonogenic bone marrow cells substantially 
increases with exposure time (4) This increase in Ara-C cytotoxicity 
was also observed for the Molt-4 clonogenic cells However, the 
magnitude of the change in cytotoxicity differed for the two 
clonogenic cell types 
Ara-C sensitivity of a certain cell type depends on both the 
proliferative state and the metabolic activity, including drug-uptake, 
drug-inactivation, drug-retention, the interaction with DNA-synthesis 
and incorporation into DNA (10,11,12,13) 
The two clonogenic celltypes used in this study differ for both 
cellkmetic state and metabolic potential Molt-4 cells are 
metabolically active and rapidly proliferating In contrast, the 
CFU-GM are at a low proliferative state, when not stimulated with CSA 
and much less metabolically active This difference in Ara-C 
sensitivity became most obvious after long-lasting exposure, the 
concentrations leading to a 90% kill of both types of clonogenic cells 
differed maximally 75 times after 72 hours exposure 
One hour exposure to Ara-C seems ineffective to accomplish a 
differential kill for clonogenic cells, since the maximal difference 
in reduction of the number of Molt-4 and CFU-GM colonies was only 2 
times One hour in vitro exposure, as used by several investigators 
to determine differential sensitivity of clonogenic cells to Ara-C 
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therefore has to be considered of limited value (1,1·+. 15) In vivo 
the use of push injections and infusions of one hour proved to be 
effective. However, these observations are based on a decrease in 
total tumor cell mass and not on elimination of clonogemc tumor 
cells. 
Ara-C scheduling has been studied extensively on cell-lines The 
optimal dose intervals for a certain cell type were calculated, using 
cytokinetic data (16,17,18,19). 
From our data it can be concluded that differential sensitivity can be 
increased by using the optimal exposure time Prolonging the exposure 
time, although greatly increasing Лга-С cytotoxicity, does not 
necessarily result in an increase of differential sensitivity 
Nevertheless, long-lasting Ara-C exposure seems more effective than 
some hours infusions or push injections. 
Furthermore, m the model presented, Ara-C differential sensitivity 
was large enough to obtain several log kill of the leukaemic 
clonogemc cells without affecting the normal clonogemc cells In 
vitro differential kill may become useful in purging bone marrow for 
autologous reinfusion The extent of differential sensitivity in 
patient-derived leukaemic clonogemc cells will be the subject for 
further studies. 
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CHAPTER 7 
IN VITRO DIFFERENTIAL SENSITIVITY OF NORMAL AND LEUKAEMIC CLONOGENIC 
BONE MARROW CELLS TO CYTOSINE ARABINOSIDE 
R Raijmakers, Τ de Witte, Ρ Muus, J Bo.ezeman, J Wessels, С Haanen 
submitted for publication in: Leukemia Research 
SUMMARY 
In vitro differential sensitivity to cytosine arabinoside (Ara-C) of 
normal and leukaemic clonogenic cells (CFU-GM and CFU-L resp ) was 
studied. Bone marrow was exposed to varying Ara-C concentrations 
during different times both in the presence and in the absence of 
colony stimulating factor (CSF). 
Short exposure to Ara-C (one hour), which can be considered 
pharmacologically equivalent to an in vivo bolus injection, did not 
result in substantial inhibition of colony growth, neither of CFU-GM 
nor of CFU-L. Continuous exposure in the presence of CSF during 5 up 
to 10 days, simulating an in vivo continuous infusion, induced a 
concentration dependent suppression of both CFU-GM and CFU-L. 
Substantial differential sensitivity to Ara-C between CFU-GM and CFU-L 
(about a factor 5) was observed in 1 out of 8 leukaemic bone marrow 
samples after 5 days exposure, and in 4 out of 8 samples after 10 days 
exposure 
Three out of 8 leukaemic bone marrow samples exhibited spontaneous 
colony formation (in the absence of CSF). In these 3 leukaemic bone 
marrow samples a pronounced differential sensitivity was observed 
after 5 days exposure in the absence of CSF 
From these data it can be concluded that in vitro differential 
sensitivity to Ara-C increases after long-lasting exposure The 
results predict an advantage in differential kill of clonogenic cells 
by continuous infusions over push injections in \ivo 
The data obtained after incubation in the absence of CSF suggest that 
differential kill between normal and leukaemic clonogenic cells 
depends on differences in the proliferative activity of the clonogenic 
cells. Manipulations uhich could induce leukaemic cell proliferation 
or inhibit the proliferative activity of the normal clonogenic cells 
may greatly enhance the differential kill by cycle specific cytotoxic 
drugs. In vitro such manipulations could be exploited for selective 
removal of tumor cells from bone marrow aspirates 
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INTRODUCTION 
The efficacy of cancer therapy depends primarily on elimination of 
malignant clonogenic cells, besides eradication of tumor cell mass 
(1,2) Furthermore, therapeutic regimens should eliminate the maximal 
number of malignant stem cells with minimal damage to the normal stem 
cell population 
Clonogenic assays offer the opportunity to measure in vitro 
differential sensitivity between leukaemic clonogenic cells and normal 
hematopoietic progenitor cells (3,4) Although one should be aware 
that clonogenic cells are not identical to real stem cells, pieces of 
evidence exist that stem cells and clonogenic cells are at least 
closely related (5) 
In this study the in vitro circumstances were studied in which 
cytosine arabinoside (Ara-C) exerts a differential suppressive effect 
on clonogenic leukaemic cells compared to normal hematopoietic 
progenitor cells The in vitro Ara-C exposure times and drug 
concentrations were varied and exposure was done both in the presence 
and in the absence of CSF After m vitro exposure the cells were 
plated in semi-solid medium for determining the effect on 
clonogenicity Also the cells were continuously exposed to Ara-C by 
addition of the drug to the semi-solid medium The results are 
discussed in view of treatment schedules 
PATIENTS, MATERIALS AND METHODS 
Patients studied. Bone marrow specimens were obtained from 8 newly 
diagnosed and untreated patients with acute myelocytic leukaemia 
Clonogenic assays always show a considerable day to day variation 
That is why all samples were thawed and assayed in one experiment 
All leukaemic bone marrow samples that appeared clonogenic in agar 
were cryopreserved for in vitro Ara-C sensitivity assays (Table I). 
The number of blast cells in the bone marrow specimens, corrected for 
peripheral blood admixture according to Holdnnet et al (6), ranged 
from 25 to 95°« Control bone marrow samples were obtained from 4 
normal volunteers. 
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Bone marrow sampling, freezinfi and thawing. Bone marrow aspirates 
were collected in buffered acid citrate dextrose (pH 7 0 ) . The 
suspension was filtered through a nylon filter (pore-size 70 vm), 
diluted with 
Table I Patient material 
Patient Diagnosis growth pattern plating cells 
no efficiency"^ plated/ml 
1 
2 
3 
4 
5 
6 
7 
8 
ANLL 
AMOL 
ANLL 
ANLL 
ANLL 
ANLL 
AMMOL 
ANLL 
ANLL,acute nonlymphocytic leukaemia, AMMOL,acute 
myelomonocytic leukaemia, AMOL,acute monocytic 
leukaemia. ^ Plating efficiency was defined as the 
number of aggregates/ 1000 cells plated 
Ca/Mg free Hanks Balanced Salt Solution (IIBSSI and centrifugated to 
romove plasma and fat The pellet was resuspended in HBBS. Density 
centrifugation was performed (20 m m , 500 g) on Ficoll (density 1,085, 
Pharmacia, Sweden) to eliminate the bulk, of red cells and 
granulocytes The interphase cells were collected, diluted with HBSS 
and washed twice The final pellet was resuspended to a final 
concentration of 2 10 cells/ml in Dulbecco's Modified Eagle's Medium 
(DMF.M) supplemented with 20o„ (v/v) Fetal Calf serum (FCS) (complete 
medium). 
Freezing and thawing were done as described earlier (7). In short. 
The cell suspension was diluted dropwise at 0°C with an equal volume 
of complete medium supplemented with 20оо (v/v) Dimethylsulfoxide 
colonies 109 5x10 
clusters 8 6 IO' 
clusters 4.3 2.5xlo' 
col+clus 1.3 5xl0' 
col+clus 4.1 2.5x10' 
colonies 13 2 5xl0' 
col+clus 2.1 5x10 
clusters 1 В 5x10 
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(DMSO). Two ml cellsuspensions were frozen in liquid nitrogen, using 
a temperature-controlled freezing program (Nicool 416) The cell 
samples were thawed rapidly at 370C, subsequently diluted and 
incubated for 10 minutes in FCS containing per ml· 70 U DNAse, 
4x10 M MgSO, and 5 U preservative-free heparin After the 
incubation the cell suspension was diluted with HBSS and centrifuged 
(10 min, 500g). The cell pellet was suspended in culturing medium and 
used for Ara-C exposure experiments. 
Ara-C exposure. All dilutions of Ara-C were made in DMEM just prior 
-3 
to use from a frozen stock solution of 10 M preservative-free 
Cytosar (Upjohn, Kalamazoo, Mich.) The drug was checked for 
concentration, purity and stability by high pressure liquid 
chromatography (HPLC) (8). 
In each experiment individual marrow cell suspensions (10 cells/ml) 
were aliquoted, 5 ml in 15 ml culturing tubes (Falcon, Becton and 
Dickinson, Paramus, NY; The сеііч were diluted in DMEM supplemented 
with 5% FCS and in part of the experiments with 5°„ (v/v) colony 
stimulating factor (CSF) After pre-incubation of the cellsuspensions 
for one hour (100% humidified atmosphere, 5% CO., in air, 37°C) , 0.1 ml 
Ara-C at increasing concentrations was added. Subsequently the 
cellsuspensions were incubated (37"C, fully humidified atmosphere of 
50„ CO in air) for 1 hour and 5 days respectively At the end of the 
exposure the 5 ml cellsuspension was diluted 2-fold with HBSS (4'IC) to 
stop further Ara-C incorporation and washed 3 times by centrifugation 
(10 m m , 500g, 4 0C). The final pellet was resuspended and used for 
clonogenic assay 
Clonogenic assay for CFU-L and CFU-GM The clonogenic assay used in 
this study is a modification of the CFU-GM assay as described earlier 
(9). All clonogenic assays were performed in duplicate in 35 mm Petri 
dishes (Costar, Cambridge, Mass ). Each dish was filled with 2 ml of 
a cell suspension The cell concentration was adapted to the plating 
efficiency, in order to obtain an adequate number of colonies per 
plate. For determination of the optimal cell concentration different 
3 5 
cell concentrations were tested before, varying between 10 and 10 
cells/ml. The cell suspension was made in DMEM, supplemented with 20% 
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FCS (v/v) from a preselected batch, 5?o (v/v) Colony Stimulating Factor 
(CSF) and 0.3% (w/v) bacto-agar (Difco, Detroit, Mich.). The CSF used 
was either derived from human placental conditioned medium (HPCM) as 
described by Verma et al (10), or it was derived from 
phytohaemagglutinin stimulated peripheral blood leukocytes of a 
patient with Hemochromatosis (PHA-LCM) (4). The plated cells were 
incubated at 370C in a fully humidified atmosphere of 5% CO in air. 
After 10 days cell aggregates of more than 5 cells were counted. 
Aggregates of more than 40 cells were defined as colonies. If only a 
few colonies were combined with a great number of clusters (aggregates 
between 5-40 cells) the colonies were included in the number of 
clusters. 
Definitions and curve fitting. The Ara-C concentrations resulting in 
90% inhibition of clonogenicity (D 90) were determined from the 
concentration-response curves. These curves were fitted, according to 
a model described by the formula: 
This function contains three features; (a) represents the maximal 
plating efficiency (=100°,,), (b) represents the concentration at which 
inhibition has become 70°», (c) represents the slope of the downward 
leg of the curve. The model was fitted according to the Gauss-Newton 
regression procedure with the use of least square criteria (11) 
Differential sensitivity was defined as the ratio between Ara-C 
concentrations necessary to obtain 90% inhibition of colony growth 
(D 90) for leukaemic clonogenic cells and normal hematopoietic cells. 
RESULTS 
After one hour exposure to 10 M Ara-C the inhibition of colony 
growth was limited for both the normal and the leukaemic clonogenic 
cells. The inhibition ranged between 0 and 41?. (mean 15.3 ± 13.8%). 
A ten- to hundred-fold increase in Ara-C exposure concentrations, 
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equivalent to pharmacologically extremely high concentrations, did not 
result m a significant increase of inhibition of clonogenicity (Table 
II) Differential sensitivity ratio's could not be calculated, as 90™ 
inhibition was obtained for neither the leukaemic nor the normal 
hematopoietic clonogenic cells. 
Long-lasting Ara-C exposure, 5 to 10 days, of all leukaemic and normal 
Table II Inhibition of clonogenicity after 1 hour Ara-C 
exposure The mean values ± SD and the range were 
calculated for all samples assayed (n=8) 
io"7 M io"6 M io"5 M 
Ara-C Ara-C Ara-C 
mean ± SD 15 3 ± 13 8 28.6 ± 18 9 29 4 ±11 6 
range 0-41 0-54 4-42 
control bone marrow samples resulted in a concentration dependent, 2 
log inhibition of colony growth 
Differential sensitivity ratio's calculated from the fitted 
concentration-response curves at the 90% inhibitory level are 
presented in Table III. 
Ara-C exposure in the presence of CSF In only one patient (no 5) a 
substantial differential sensitivity (defined as a difference of more 
than 5 times in the Ara-C concentration to obtain 90» kill) was found 
after 5 days exposure in the presence of CSF. In 5 other samples 
assayed the leukaemic clonogenic cells were more sensitive than the 
normal controls, but the differences were less pronounced Ten days 
exposure in agar in the presence of CSF resulted in substantial 
differential sensitivity in 2 out of 8 samples (patients no 2 and 8). 
Differential bensitivity increased in 4 out of 8 samples when the 
exposure time was prolonged from 5 to 10 days (patients no 1,2,4,8) 
and decreased in 2 out of 8 samples (no 6,7) 
Ara-C exposure in the absence of CSF In the 5 days Ara-C exposure 
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assay without the addition of CSF the differences in sensitivity 
appeared more pronounced. In 3 of the 8 leukemias differential 
sensitivity was substantial, and in all these cases the leukaemic 
clonogenic cells were more sensitive (no 2,5,7). These 3 leukaemic 
bone marrow samples showed spontaneous colony formation in agar (in 
the absence of CSF), in contrast with the other 5 leukaemias and the 
norma] control samples. 
Table III Differential sensitivity to Ara-C after 5 days 
exposure with and without CSF and after 10 days exposure 
with CSF in semi-solid medium. 
Patient 5 days 10 days 5 days 
no +CSF +CSF (in agar) -CSF 
1 
2 
3 
4 
5 
6 
7 
8 
3 . 3 
0 . 4 8 
1.0 
0 . 6 8 
0 .20 
0 . 8 3 
0 .37 
0 .42 
0 .85 
0 . 1 4 
1.0 
0 .26 
0 . 2 4 
1.0 
0 . 7 5 
0 .19 
1.2 
0 .07 
0 . 8 8 
0 .50 
0 . 0 8 
0 .52 
0 .20 
0 .44 
Differential sensitivity is presented as the ratio between 
the D 90 of the leukaemic and the D 90 of the normal 
clonogenic cells. D 90 is the Ara-C concentration resulting 
in 90% inhibition of clonogenicity. Ara-C exposure was 
performed as described in the text. 
As we know from our previous experiments, Ara-C is inactivated during 
in vitro incubation (12). The fraction of Ara-C left after 5 days 
exposure of 10 cells/ml varied between 84?,, and less than 1% of the 
original concentrations (Table IV). In case of normal bone marrow 
cells the residual Ara-C concentration was about 55%. No correlation 
could be found between the amount of Ara-C left after 5 days exposure 
and the change in differential sensitivity after prolonging the 
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exposure time. The rate of deamination was not influenced by the 
addition of CSF during the 5 days exposure. 
Table IV Ara-C fraction left in the medium after 5 days 
-6 -5 -4 
exposure at 10 , 10 and 10 M Ara-C initial 
concentration 
patient 
control 
(n=4) 
1 
2 
3 
4 
5 
6 
7 
β 
nd=noC done 
DISCUSSION 
Initial Ara-C concentrations (M) 
Hf6 
52 
0 
77 
12 
-
83 
19 
13 
nd 
io"5 
56 
0 
68 
8 
47 
83 
2 
6 
nd 
io'4 
61 
0 
74 
5 
51 
82 
17 
15 
nd 
In this study in vitro clonogenic assays were used to investigate the 
optimal conditions for elimination of residual leukaemic clonogenic 
cells with minimal damage to the normal hematopoietic clonogenic 
cells. 
In conventional predictive assays for Ara-C sensitivity the clonogenic 
cells are either exposed to Ara-C for one hour, or they are cultured 
in the presence of Ara-C (13,14,15,16,17). 
The results from this study clearly indicate the ineffectiveness of 
short Ara-C exposure to accomplish differential kill between leukaemic 
and normal hematopoietic clonogenic cells. 
After 5 days exposure at increasing Ara-C concentrations a complete 
- 97 -
kill of both the normal and leukaemic clonogenic cells could be 
attained. 
Differences of more than 5 times in the Ara-C concentration that 
resulted in 90«. kill of the normal and leukemic clonogenic cells were 
defined substantial. Using this definition a substantial differential 
kill was obtained in only 1 out of 8 samples assayed after 5 days 
exposure and 2 out of the 8 samples after 10 days exposure. 
Prolonging the exposure time from 5 to 10 days showed increase as well 
as decrease in differential sensitivity. Besides the cytotoxicity of 
Ara-C increased with the exposure time. 
In contrast to the limited differential sensitivity between leukaemic 
and normal clonogenic cells after 5 respectively 10 days exposure in 
the presence of CSF, large differences were found in 3 of the 8 
leukaemias after 5 days exposure in the absence of CSF. These 3 
leukaemic samples showed spontaneous colony growth in semi-solid 
medium. These results stress the importance of the proliferative 
state of the clonogenic cells in case of an S-phase specific drug like 
Ara-C. 
Consolidation treatment schedules, instituted to eliminate residual 
leukaemic clonogenic cells, are not based on data about the 
proliferative state of the normal and leukaemic clonogenic cells. In 
vitro however, the use of stimulating and inhibitory factors could be 
exploited to increase differential kill between normal hematopoietic 
and leukaemic clonogenic cells, contaminating bone marrow aspirates 
(18). 
In vitro Ara-C exposure is complicated by cellular drug inactivation, 
which becomes more pronounced after long-lasting exposure and at 
increasing cell concentrations during Ara-C exposure (12). Large 
differences were found in the rate of deamination for the different 
normal and leukaemic samples, despite the use of relatively low cell 
concentrations during the Ara-C exposure. However, no correlation was 
found between the extent of deamination after 5 days exposure and 
differential sensitivity. Although no such correlation was found, 
Ara-C deamination may become significant in case higher cell 
concentrations (> 10 cells/ml) are used during Ara-C exposure, 
because the extent of deamination increases with increasing cell 
concentrations (12). 
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Based on the experiments m this study some conclusions can be drawn 
The in vitro differential sensitivity is most obvious after 
long-lasting exposure to Ara-C This suggests that continuous 
infusion of Ara-C is more effective to suppress residual leukaemic 
clonogenic cells than bolus injections In vitro clonogenic assays 
cannot be used to predict for differential sensitivity in individual 
patients, as the in vivo and in vitro proliferative status may be 
totally different 
In vitro differential sensitivity may offer an approach to eliminate 
leukaemic clonogenic cells from bone marrow aspirates, but 
long-lasting Ara-C exposure should be instituted 
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CHAPTER 8 
IN VIVO CELLULAR ADRIAMYCIN CONCENTRATIONS RELATED TO INHIBITION OF 
NORMAL AND LEUKAEMIC HUMAN CLONOGENIC BONE MARROW CELLS 
Ρ Speth, R Raijmakers, J Boezeman, Ρ Linssen, Τ de Witte, J Wessels, С 
Haanen 
submitted to: Cancer Research 
SUMMARY 
Inhibition of clonogenicity of normal and leukaemic human 
hematopoietic progenitor cells was studied after in vivo and in vitro 
exposure of bone marrow to adriamycin (ADM). The measured inhibition 
of clonogenicity correlated well with cellular ADM concentrations in 
blast cells determined with flow cytometry and expressed in 
fluorescence units/cell (FU/cell). 
After 2 hours in vitro exposure to 500 ng ADM/ml, the ADM 
concentration of leukaemic and normal bone marrow blast cells amounted 
254 ± 158 and 249 ± 53 FU/cell respectively, which resulted in a 
moderate decrease of clonogenicity of 44 ± 30 and 54 ± 27%. Exposure 
to 2000 ng/ml revealed cellular ADM concentrations of 1184 ± 472 
FU/cell and 1024 ± 281 FU/cell, resulting in an almost complete 
inhibition of clonogenicity of 96 ± 7% (leukaemic) and 99 ± 1% (normal 
bone marrow). No apparent differential toxicity between leukaemic and 
normal clonogenic cells was noted. 
2 
After in vivo ADM administration of 30 mg/m on three subsequent days, 
drug concentrations in blast cells amounted not more than 216 ±98 
FU/cell, implying that inhibition of clonogenicity after 
administration of conventional dosages will be circa 50% for both 
leukaemic and normal bone marrow progenitor cells. 
From these data it can be concluded that the in vivo attained cellular 
ADM concentrations are too low to result in a complete eradication of 
leukaemic clonogenic cells, although substantial reduction of the 
number of tumor cells can be attained. In vitro ADM sensitivity 
testing on clonogenic cells has no predictive value for the ultimate 
clinical response, as the in vitro observed cellular ADM 
concentrations resulting in a complete inhibition of clonogenicity are 
never attained in vivo. 
INTRODUCTION 
Anthracyclines are incorporated in most standard regimens for 
remission induction therapy in adult acute nonlymphocytic leukaemia 
(1,2). Pharmacokinetic studies have revealed a large drug 
distribution volume consistent with a considerable drug uptake in an 
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extravascular compartment (6,10) Plasma pharmacokinetic studies did 
not show any correlation between pharmacologic parameters and the 
ultimate clinical result (2,14,18) Studies on cellular anthracycline 
concentrations (2,12,19) revealed observed cellular drug 
concentrations 500 to 800-fold higher than those in plasma. 
Parameters of cellular and plasma pharmacokinetics appeared completely 
different from each other. 
Cellular adriamycm (ADM) concentrations occurring in vivo after drug 
administration show prolonged drug retention during several days 
(12,19) The same intracellular drug persistence is observed after in 
vitro incubation (13,16). 
In this study the extent of cytotoxicity of cellular ADM 
concentrations for normal and leukaemic clonogenic bone marrow cells 
was determined. These in vitro cellular ADM concentrations were 
compared with the in vivo cellular ADM concentrations after ADM 
administration 
MATERIALS AND METHODS 
Patients Patients were treated according to the AML-6 protocol of 
the European Organisation on Research and Treatment of Cancer 
2 
consisting of Adriamycm 30 mg/m" bolus injection on day 1,2 and 3, 
vincristine 1 mg/m"" bolus injection on day 2 and seven days of 
2 
cytosme arabinoside 50 mg/m bolus injection twice daily with 100 
2 
mg/m as 24 hour continuous infusion 
Chemicals Adriamycm (ADM) was obtained from Roger Bellon (Neuilly 
sur Seine, France). Pure ADM and Adnamycinol for chromatographic 
purposes were kindly provided by Prof.Dr.F Arcamone (Farmitalia Carlo 
Erba, Milan, Italy). All further chemicals used were obtained from 
Merck (Darmstadt, Germany) and were of analytical grade 
Bone marrow sampling and storage Bone marrow aspirates from 7 newly 
diagnosed patients with acute nonlymphocytic leukaemia and 4 normal 
bone marrow aspirates were collected and stored in liquid nitrogen 
(4). 
Bone marrow was collected m Acid Citrate Dextrose (ACD-A buffer, pH 
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7.4). After washing with Hanks Balanced Salt Solution (HBBS) the 
cells were layered on a Percoli cushion (density 1.085 g/ml, pH 7.4, 
300 mosmol/kg). Cells from the interphase were washed twice and 
resuspended in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with 20% Fetal Calf Serum (FCS). Prior to storage the cell suspension 
was diluted 1:1 with 20% (v/v) Dimethylsulphoxide in DMEM. Cell 
suspensions were cryopreserved in a number of 2 ml vials (Nunc, 
Intermed, Copenhagen, Denmark) using a temperature-controlled freezing 
procedure (4) and stored in liquid nitrogen. 
Cryopreserved bone marrow was used for in vitro ADM exposure to 
circumvent day to day variations in the culturing conditions. 
In vitro ADM exposure. Cryopreserved bone marrow cells of 7 patients 
with acute nonlymphocytic leukaemia and 4 healthy volunteers were 
rapidly thawed, incubated during 10 minutes with DNAse, washed, 
counted and resuspended in Tris-buffered DMEM supplemented with 10% 
FCS at a final cell concentration of 10 cells/ml (4). After 30 
minutes preincubation, ADM was added to final concentrations ranging 
from 50 to 2000 ng/ml. The samples were incubated for two hours, as 
previous studies (20) had revealed that then an equilibrium was 
reached in the concentration range studied. To calculate the loss of 
cellular ADM during the washing procedure at the end of the incubation 
a sample was taken for flow cytometric determination of the ADM 
concentration in blast cells as described below. Subsequently cells 
were washed twice with cold HBBS and resuspended in culture medium and 
just prior to plating the cellular ADM was determined for a second 
time. 
Clonogenic assay for leukaemic and normal colony forming units. The 
assay of the committed myeloid progenitor cells for normal (CFU-GM) 
and leukaemic (CFU-L) bone marrow cells has been described earlier 
(3). All assays were performed in duplicate in 35 mm Petri dishes 
containing 2 ml of the cell suspension. The optimal cell 
concentrations used were determined before in order to obtain an 
adequate number of colonies per dish. The cell suspensions were made 
in DMEM, supplemented with 20% FCS (v/v), 5% (v/v) placenta 
conditioned medium as a source of colony stimulating factor and 0.3% 
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(w/v) Bacto agar (Difco, Detroit, Michigan, USA). Cultures were 
incubated at 370C in a fully humidified atmosphere of 5% CO in air. 
After 12 days cell-aggregates consisting of 40 cells or more were 
scored as colonies and aggregates of 5-40 cells as clusters. 
Collection of patient samples after in vivo ADM administration. The 
range of cellular ADM concentrations attained in vivo up to 168 hours 
after ADM infusion was determined. Bone marrow samples were obtained 
of 8 patients with acute nonlymphocytic leukaemia and 3 patients with 
Hodgkin's disease without bone marrow infiltration. The procedure has 
been described before (20): the samples were collected in ice-cold 
ACD-A and filtered through a 70 ym filter. Peripheral blood admixture 
in the suspension was determined (7) to exclude from the study samples 
with more than 20% nucleated blood cells. Erythrocytes and 
normoblasts were lysed with ammonium chloride. The remaining white 
cells were resuspended in ice-cold Phosphate Buffered Saline (PBS). 
Part of the suspension was stored at -20°C for analysis with high 
pressure liquid chromatography (HPLC), part was kept on ice for flow 
cytometric (FCM) determination of cellular ADM concentration usually 
within a few hours. 
Since in preliminary studies a good correlation was found between ADM 
concentrations in simultaneously sampled nucleated blood cells and 
bone marrow cells, blood samples were taken to determine ADM 
pharmacokinetic parameters. Blood samples were drawn in heparinized 
polypropylene tubes, kept at 00C to stop further ADM metabolism. 
Samples were centrifugated at 900 g for 10 min at 0°C, plasma was 
removed and stored at -20''C until analysis. Erythrocytes and 
normoblasts in the pellet were lysed and the cell pellet was processed 
as described above. 
Determination of cellular ADM concentration. Cellular ADM 
concentrations in blast cells were determined with 3 parameter laser 
flow cytometry (FCM) as has been described previously (20). In short: 
cell samples were analysed using a 50H Cytofluorograph (Ortho 
Diagnostic Systems Ine, Westwood, MA, USA), equipped with a 5 W Argon 
laser (164-05, Spectra Physics, Mountain View, USA) exciting at 488 nm 
with an output of 500 mW. Combination of forward and perpendicular 
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light scatter signals enabled identification of cell subsets like the 
blast cell population, lymphocytes, myeloid cells and cell debris 
(20). Due to its fluorescent properties, cellular ADM concentrations 
can be determined in cells of distinct subpopulations and expressed in 
arbitrary Fluorescence Units/cell (FU/cell) corrected for 
autofluorescence by subtraction of the blank value. Of each sample at 
least 10,000 cells were analysed at a flow rate of 1000 cells/sec. 
Data of cellular ADM concentrations obtained by flow cytometry 
correlated with the results of the determination by HPLC 
(r = 0.94)(20); 100 FU/cell appeared to correspond with 4 fg/cell, 
9 
assuming the volume of 10 cells to be 1 ml. Cells from each 
subpopulation were sorted to verify their identity microscopically. 
Measurement of plasma and cellular ADM by HPLC. The HPLC method used 
was described before (20). In brief; 10 cells were sonicated for 15 
s at 75 W with a MSE Soniprep 150 Ultrasonic Disintegrator (MSE 
Scientific Instruments, Crowley, UK). To 250 vl cell suspension or 
500 vl plasma 3 ml chloroform/methanol 9:1 (v/v) was added, followed 
by 100 yl tris buffer (1 M, pH 8.7) containing daunomycin as internal 
standard. After two extractions with chloroform/methanol 9:1 (v/v), 
the chloroform phase was collected and evaporated. The residue was 
dissolved in 750 ui chloroform/methanol, with addition of 50 ul tris 
buffer. A 500 ul sample was injected into the column (Lichrosorb 
5SÌ60 column 100 χ 3.0 mm ID). The column was eluted with chloroform, 
methanol, glacial acetic acid, and 0.3 mM MgCl (720:210:40:30 v/v) 
under addition of desipramine 10 mg/1. Detection was carried out with 
a fluorometer (λ-excitation at 488 nm, λ-emission above 550 nm)(FS 970 
L.S. Fluorometer, Schoeffel Inst. Corp, Ramsey, NJ). Quantitation 
of the drug concentration was achieved by measurement of the peak 
height ratio of drug and internal standard and calculated from a 
calibration curve of peak height versus concentration. The detection 
limit of ADM and metabolites was determined at 1 ng/ml. The 
within-day precision of the method (n=17) was 7.0%. 
Statistical analysis. Data obtained from the clonogenic assays and 
from the measurements of cellular ADM concentrations were analysed for 
statistical significance using the Wilcoxon 2-sample test. 
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RESULTS 
Flow cytometric discrimination of the blast cell population. 
Multiparameter flow cytometry of normal and leukaemic bone marrow 
samples enabled discrimination of the blast cell subpopulation based 
on cellular forward and perpendicular light scatter signals. The 
higher the percentage of blast cells in the suspension, the higher the 
number of blast cells in the scatter defined rectangle indicated in 
fig 1, as was concluded from microscopical examination after sorting. 
In a normal bone marrow sample containing l-2°o blast cells, over 60?« 
of the blast cells were found in the cell scatter rectangle indicated 
in fig 1A, together with erythroblasts, monocytes and non-blastic 
myeloid cells. In leukaemic bone marrow with more than 40°. blast 
cells close to 100% blast cells were found in the scatter window 
indicated (fig 1С). Moreover, viable cells can be studied separately 
from dead cells and cell debris. Especially when cryopreserved bone 
marrow is used, the number of dead cells and debris is relatively high 
(fig IB, 1С). After in vitro incubationb with ADM, dead cells and 
cell debris outside the scatter defined, window appeared to contain 
more than twice as much ADM compared to the viable cells (fig 2C). 
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Fig 1 : Two parameter (forward and perpendicular) light scatter plot 
of fresh normal bone marrow (A), cryopreserved normal bone marrow (B) 
and cryopreserved bone marrow of a patient with acute nonlymphocytic 
leukaemia (C). The blast cell subpopulations are indicated by the 
rectangle (3). Note the number dead cells (1) and cell debris (5) in 
the cryopreserved bone marrow samples. Population 2 consists of 
lymphocytes and population 4 of mature myeloid cells. 
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Fig 2: Forward and perpendicular light scatter plot of a leukaemia 
bone marrow (A). Fluorescence versus scatter plot of the blank (B) 
and after in vitro exposure to 500 ng ADM/ml for 2 hours (C). Note 
the ADM accumulat ion in the rectangle (5), containing dead cells and 
cell debris. 
Cellular ADM concentrations in vitro. Cellular ADM concentrations in 
blast cells were determined both at the end of the in vitro ADM 
exposure and just prior to plating. For both leukaemic and normal 
bone marrow cells a linear correlation was found between the 
extracellular ADM concentrations and the resulting blast cell ADM 
concentrations (n=8, r-value always better than 0.95), which implies 
an essentially non-saturable cellular ADM uptake. After washing just 
prior to plating a proportional loss of 48± 11* of the initial 
cellular ADM was observed over the ADM concentration range tested, 
indicating a free cellular ADM fraction of about 50?» which was removed 
during the washing procedure. 
Cellular ADM concentrations in vivo. An example of a plasma and 
cellular (blast cells) ADM concentration-time curve is shown in fig 3. 
2 
ADM (30 mg/m ) was administered as a one min bolus injection. In the 
blast cells a short-lasting peak-cellular ADM concentration of 96 
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Fig 3: CelJular and plasma ADM concent rat ion-t ime curve 
2 during the first 60 minutes after 30 mg/m ADM bolus 
injection (1 mm) m a leukaemic patient. (9)= ADM 
concentrations m leukaemic cells (expressed m FU/cell 
(left) and m ng/ml (right) respectively, assuming 109 
cells representing a volume of 1 ml). (0)= plasma 
concentration of adnamycm m ng/ml. (Ώ)= plasma 
concentrations of the metabolite adriamycmol in ng/ml. 
9 
FU/cell (4160 ng/10 cells) at 1.5 m m after the start of the infusion 
is followed by a longer-lasting plateau-concentration from 10 rain on 
of about 60 FU/cell. At 24 hours the cellular ADM concentration still 
amounted 46 FU/cell. 
The time-course of cellular ADM concentrations in leukaemic and normal 
blast cells was determined in 8 patients with acute leukaemia and 3 
patients with a malignant disease without bone marrow involvement, up 
to 72 hours after ADM infusion. ADM (30 mg/m") was administered 
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during 3 subsequent days. 
Maximum cellular ADM concentrations, measured within 5 minutes after 
the end of the administration in leukaemic and normal blast cells on 
three subsequent days, amounted 96 ± 29 FU/cell, 173 ± 58 FU/cell and 
216 ± 98 FU/cell respectively. ADM accumulates after repeated 
injections. In general, the maximum cellular ADM concentration after 
bolus injection decreased rapidly with 30-50?i, comparable to the rapid 
loss observed after in vitro incubation and reincubation (16). 1 to 2 
hours after the termination of the drug infusion the apparently 
"bound" cellular ADM concentrations were 6 2 + 2 0 , 97 ± 43 and 
122 ± 50 FU/cell respectively, persisting for several days. In 
contrast with the moderate decrease of cellular ADM concentrations, 
plasma concentrations were reduced by 2 to 3 decades, from maximum 
concentrations at 5 min of over 8000 ng/ml to 10-30 ng/ml after 2 
hours. 
Clonogenicity and cellular ADM concentration in vitro. After 2 hours 
exposure of leukaemic and normal bone marrow to less than 100 ng 
ADM/ml, clonogenicity of leukaemic cells was depressed 20 ± 17« 
(normal bone marrow 8 ± 9%). Moderate suppression of 44 ± 30?o (normal 
bone marrow 54 ± 27?¿) was observed after 2 hours in vitro exposure to 
500 ng ADM/ml (fig 4), resulting in cellular drug concentrations of 
254 ± 158 FU/cell (normal bone marrow 249 ± 53 FU/cell). Two hours 
exposure to 1000 ng/ml resulted in 850 ± 421 FU/cell (normal bone 
marrow 641 ± 112), and inhibition of clonogenicity of 86 ± 12% 
(normals 94 ± 5%). At extracellular concentrations of 2000 ng/ml both 
normal CFU-GM and leukaemic CFU-L were almost completely inhibited 
(fig 4) (leukaemic cells 9 6 + 7 and normal cells 99 ± Π;) at ADM 
concentrations in the leukaemic blast cells of 1184 ± 472 FU/cell 
(normal bone marrow 1024 ± 281 FU/cell). The D 50 (the percentage at 
which 50% inhibition of clonogenicity was obtained) was reached at 
230 + 102 FU/cell after 2 hours exposure to 545 ± 252 ng/ml. The D 90 
was reached at cellular ADM concentrations of 936 ± 240 FU/cell after 
2 hours exposure to 1146 ± 166 ng/ml (table I). Cellular ADM 
concentrations in leukaemic blast cells (n=7) were in the same range 
as those obtained in normal bone marrow blast cells (n=4) (no 
significant differences). 
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Fig 4: Inhibit ion of clonogenicity after 2 hours incubation plotted 
against ADM concentration in the medium. Dotted lines are normal 
controls, draun lines are loukaemic samples. 
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Table I In vitro adriamycin sensitivity of myeloid 
progenitor cells from patients with acute nonlymphocytic 
leukaemia and normal controls 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
mean ± ! 
Control 
Control 
Control 
Control 
mean ± '. 
5D 
1 
2 
3 
4 
5D 
blasts 
(5o in sample) 
96 
71 
72 
89 
65 
25 
49 
2 
3 
1 
0 
D 90 
(ng/ml) 
1360 
966 
1170 
1040 
1390 
1154 
940 
1146 
751 
850 
1100 
943 
911 
+ 
± 
166 
129 
D 90 
(FU/cell) 
1030 
999 
1090 
984 
1260 
477 
712 
936 ± 
706 
487 
911 
610 
679 ± 
240 
155 
Cellular ADM concentrations in vivo In fig 5 the range of blast cell 
ADM concentrations is indicated attained in the treatment of acute 
2 
leukaemia after 3 repeated administrations of ADM (30 mg/m ) The 
highest inhibition of clonogenicity which can be expected from the in 
vivo observed cellular ADM concentrations is circa 65% (fig 5) 
In a patient with Hodgkin's disease without bone marrow involvement, 
clonogenicity was determined of bone marrow cells obtained before, as 
well as after 5 m m and 2 hours after an ADM bolus injection of 50 
2 
mg/m" By then the number of colonies was reduced to 13% and 19% 
respectively (blast cells ADM concentration: 144 and 71 FU/cell 
resp) 
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Fig 5: Inhibition of clonogenicity plotted against "bound" cellular 
ADM concentrations. Dotted lines are normal controls, drawn lines are 
leukaemic samples. The hatched area represents the 'bound" blast cell 
ADH concentrât ions observed 1 to Ζ hours after in vivo administration 
( n=Z4). 
DISCUSSION 
One of the modes of action of ADM is considered to be the binding to 
DNA by intercalation between base pairs. In a number of cytotoxicity 
studies using cell-lines, resistance to ADM appeared only marginally 
related to differences in the rate of uptake (8), but almost 
completely to the cellular retention of the drug. 
In this study human hematopoietic clonogenic cells were exposed to ADM 
in vitro as well as in vivo. Inhibition of clonogenicity was related 
to blast cellular ADM concentrations. 
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Flow cytometry enables measurement of cellular ADM concentrations in 
small numbers and in viable cells of distinct subpopulations (9,20) 
With fluororaetnc or chromatographic techniques (21) however, the 
contribution of the relatively high proportion of ADM in dead cells 
and debris (Fig 2c) can not be specified (13,9) 
In this study no significant differences in cellular ADM retention 
were noted between leukaemic blast cells of different patients, nor 
between leukaemic and normal blast cells Also no difference in 
inhibition of clonogenicity was observed, which confirms data by Buick 
et al (1) and is in contrast to other studies (11,15) 
A good correlation was observed between the cellular ADM concentration 
in leukaemic and normal blast cells and inhibition of clonogenicity 
It appeared that the highest cellular ADM concentrations observed in 
vivo were far less than the drug concentrations which appear to result 
in vitro in complete inhibition of clonogenicity (13,15) 
Opposite to studies by Park et al (11), our study gives no support for 
the assumption that the clonogenic assay can be used as a predictive 
test for the ultimate clinical response to ADM chemotherapy This is 
due to the limited range of cellular ADM concentrations which can be 
attained in vivo (22) and due to the lack of differential toxicity 
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SUMMARY AND CONCLUSIONS 
Autologous bone marrow transplantation (ABMT) shortens the period of 
bone marrow aplasia after bone marrow ablative treatment The 4 major 
factors that determine the success of ABMT are 1) the repopulation 
capacity of the cryopreserved and reinfused bone marrow cells after 
thawing and reconstitution, 2) the efficacy of the bone marrow 
ablative therapy to eradicate the (clonogenic) tumor cells in the 
host, 3) the toxic side-effects of the conditioning regimen in the 
patient and 4) the number of residual (clonogenic) tumor cells present 
in the aspirate The aim of this study was to improve the safety of 
the procedure and to investigate the feasibility to eliminate residual 
clonogenic cells in vitro using cytotoxic drugs 
In Chapter 1 modifications in the procedure of bone marrow enrichment 
and cryopreservation are described To reduce the volume of the 
aspirate and to remove the bulk of erythrocytes and mature 
granulocytes, a rapid and safe method was developed using 
discontinuous cell separation A better recovery of the cryopreserved 
clonogenic cells was obtained by temperature-controlled freezing of 
the enriched cell fraction in autologous plasma and 10°„ DMSO 
Long-lasting storage did not dimmish the viability of the clonogenic 
cells The thawing procedure, monitored by the cell viability in test 
vials, was improved Furthermore the reproducability of cell 
viability assessment after thawing was improved by a deliberate choice 
of the optimal source of colony stimulating factor 
In Chapter 2 a method is described for reduction of the bone marrow 
aspirate volume with removal of the bulk of erythrocytes and SO"» of 
the nucleated cells, using a discontinuous blood cell separator The 
principle of the method, isopycnic density separation, has proven to 
be feasible on a small scale Using this semi-automated procedure 
comparable enrichment results could be obtained on a large scale with 
unimpaired repopulation capacity 
The results of ABMT m 11 patients with acute leukaemia and 8 patients 
with a solid tumor are described in Chapter 3 Repopulation was 
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obtained in all but 3 patients These 3 patients, all in relapse of 
acute leukaemia, received a rather low number of clonogemc cells. 
The 16 patients who received more than 2 10 CFU-GM/kg showed complete 
recovery of their bone marrow function. No correlation was found 
between the repopulation time in these 16 patients and the number of 
reinfused CFU-GM. ABMT has shown to be a safe procedure provided that 
an adequate number of stem cells is given Antitumor effect of bone 
marrow ablative therapy was of limited value in the more advanced 
stages of disease ABMT is expected to be useful in early phases of 
the disease, with a minimal load of clonogemc tumor cells This has 
to be proven in prospective controlled randomized trials. 
The feasibility of in vitro elimination of malignant clonogemc cells 
was studied in the second part of this thesis Differential 
sensitivity between normal and leukaemic clonogemc bone marrow cells 
from patients with acute nonlymphocytic leukaemia was determined for 2 
drugs cytosine arabinoside (Ara-C) and adriaraycm (ADM). Since 
limited data were available on the optimal in vitro exposure 
conditions for each drug, the relation between exposure time and drug 
concentration on inhibition of clonogemcity were studied first 
Chapter 4 deals with the effect of different Ara-C concentrations and 
exposure times upon clonogemcity of normal bone marrow cells. One 
hour Ara-C exposure, even at pharmacologically very high Ara-C 
concentrations, was hardly cytotoxic for clonogemc cells. Prolonged 
exposure resulted in a steep increase in Ara-C cytotoxicity, provided 
that Ara-C inactivation during the exposure was limited. Drug 
inactivation by deamination appeared cell concentration dependent, 
which implicated the use of low cell concentrations during 
long-lasting Ara-C exposure, or a continuous supply of Ara-C to 
maintain constant exposure concentration«». 
Long-lasting Ara-C exposure, even at pharmacologically very low Ara-C 
concentrations, appeared deleterious for clonogemc cells. 
In Chapter 5 cytotoxic effects of ADM on clonogemc bone marrow cells 
are presented for different exposure times and drug concentrations 
The attained cellular drug concentrations were measured by flow 
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cytometry. The achieved cellular ADM concentrations after 
reincubation correlated with the cytotoxic effect, irrespective 
whether these concentrations were attained after a short exposure to 
high ADM concentrations or after a long-lasting exposure to low ADM 
concentrations. 
In Chapter 6 in vitro differential kill for Ara-C, determined in a 
model system, is described. Normal bone marrow cells were mixed with 
tumor cells from a leukaemic cell-line. The cytotoxic effect of one 
hour Ara-C exposure was limited, even at pharmacologically extremely 
high Ara-C concentrations. This means that short-lasting exposure is 
not suitable for in vitro differential kill. Ara-C cytotoxicity 
increased up to 100 times by prolonging the exposure time from one 
hour to several days. Simultaneously differential sensitivity 
increased, with an optimum, for the clonogenic cells used in this 
study, at 72 hours. It was shown that a 100-fold reduction in the 
number of clonogenic tumor cells can be attained by long-lasting Ara-C 
exposure, without significantly affecting normal clonogenic cells. 
The results of differential sensitivity of normal and leukaemic 
clonogenic cells to Ara-C is described in Chapter 7. The cytotoxic 
effect of one hour Ara-C exposure appeared limited for both the normal 
and the leukaemic clonogenic cells. Prolonged exposure for 5 or 10 
days in the presence of colony stimulating factor (CSF) was cytotoxic 
for both clonogenic cell types. Substantial differential sensitivity 
was observed in 1 out of 8 leukaemic samples after 5 days exposure and 
in A out of these 8 samples after 10 days exposure. Three out of the 
8 leukaemic samples showed spontaneous colony growth in the absence of 
CSF. In these 3 cases a much more pronounced differential kill could 
be obtained after 5 days exposure without CSF. From these data it can 
be concluded that in vitro differential sensitivity increases after 
long-lasting exposure and can be greatly increased exploiting 
differences in the proliferative state of the clonogenic cells. Such 
differences may be exploited for elimination of residual leukaemic 
clonogenic cells from bone marrow aspirates. 
Differential kill between human normal and leukaemic clonogenic cells 
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was determined also after in vitro ADM exposure (Chapter 6). The data 
of the inhibition of clonogenicity were compared with the 
intracellular ADM concentrations and appeared to be closely related. 
The intracellular ADM concentrations as well as the inhibiton of 
clonogenicity for both the normal and the leukaemic clonogenic cells 
were within a narrow range. We therefore concluded that the use of 
ADM to obtain differential kill between normal and leukaemic 
clonogenic cells is of limited value. 
The intracellular ADM concentrations that appeared cytotoxic for the 
clonogenic cells were also compared with the intracellular 
concentrations attained after in vivo ADM administration. It appeared 
that the in vivo attained cellular ADM concentrations were far beneath 
the levels needed in vitro to arrive at a complete eradication of the 
leukaemic clonogenic cells. The kill of clonogenic cells that can be 
expected after in vivo ADM administration in conventional dosage 
2 
schemes (30-50 mg/m ) will not be higher than 50%. 
General conclusions 
The modifications in the procedure for ABMT as described in this 
thesis in combination with the quality control using clonogenic assays 
have contributed to the safety of ABMT. 
In case of a large tumor-load the success of ABMT will be limited. 
The indications for ABMT should be restricted to therapy-sensitive 
tumors in an early phase of the disease with minimal tumor load. 
Initial cytoreductive chemotherapy can be instituted, but in that case 
the quality of the bone marrow should be checked by clonogenic assays 
before bone marrow harvesting. 
The studies on differential sensitivity of normal and leukaemic 
clonogenic cells to Ara-C and ADM have not yet been proven applicable 
for bone marrow purging in a clinical setting. Adriamycin did not 
appear to be more cytotoxic to leukaemic clonogenic cells than to 
normal clonogenic cells. For that reason it is not expected that ADM 
is suitable for in vitro bone marrow purging. 
Ara-C showed substantial differential kill in some leukaemic bone 
marrow samples, after long-lasting exposure to low Ara-C 
concentrations. In case differences in the proliferative state 
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existed differential kill was even more prominent. Substances that 
can selectively alter the proliferative state of normal versus 
leukaemic clonogenic cells enable Ara-C exposure as a rationale 
procedure for elimination of residual leukaemic clonogenic cells in 
vitro. 
SAMENVATTING EN CONCLUSIES 
Autologe beenmergtransplantatie (ABMT) іь een procedure om een sneller 
en zekerder herstel van de beenmergfunctie te garanderen indien zeer 
intensieve radio- en/of chemotherapie wordt gegeven die de tolerantie 
van het gezonde beenmerg overschrijdt Dankzij deze procedure kunnen 
hoge doses antikanker therapie borden toegepast waardoor een meer 
efficiente eliminatie van tumorcellen kan worden bereikt De ABMT 
procedure bestaat uit het verzamelen van voldoende stamcellen uit het 
beenmerg, deze op te slaan en na de therapie weer toe te dienen via 
een infuus in de bloedbaan Daar het beenmerg buiten het lichaam een 
beperkte overleving heeft (maximaal 7 dagen) wordt het meestal 
ingevroren en opgeslagen in vloeibare stikstof (-1960C) 
De 4 factoren die het succes van ABMT bepalen zijn, 1) de efficiëntie 
waarmee gedurende de intensieve therapie de tumorcellen in de patient 
worden opgeruimd, 2) de bijwerkingen van de therapie op de gezonde 
weefsels en organen, 3) de kwantiteit en kwaliteit van de 
geinfundeerde stamcellen die het beenmergcompartiment moeten 
repopuleren, 4) de effectiviteit van methoden waarmee eventueel in het 
verzamelde beenmerg aanwezige tumorcellen voor het teruggeven kunnen 
worden verwijderd 
De in dit proefschrift beschreven studies betreffen enerzijds een 
verbetering van de bestaande methode om beenmergcellen te verzamelen, 
te verrijken voor hematopoietische stamcellen en in te vriezen zonder 
verlies aan viabiliteit Veel aandacht is besteed aan de 
kwaliteitscontroles tijdens de diverse stappen Anderzijds is de 
mogelijkheid onderzocht om met behulp van chemotherapeutica in vitro 
een selectieve eliminatie van tumorcellen met behoud van de gezonde 
stamcellen te bewerkstelligen 
In hoofdstuk 1 worden een aantal modificaties beschreven van de 
methoden waarmee stamcellen uit het beenmerg kunnen worden verrijkt en 
ingevroren Gebruik makend van een discontinue celscheider werd een 
procedure ontwikkeld om het volume van het beenmergaspiraat te 
reduceren en tevens het merendeel van de erythrocyten en rijpe 
granulocyten uit het aspiraat te verwijderen zonder noemenswaardig 
verlies van beenmergstamcellen De kwaliteit van invriezen werd 
aanzienlijk verbeterd door gebruik te maken van een 
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temperatuur-gestuurd invriesprogramma waardoor de viabiliteit van de 
donogene cellen volledig behouden blijft, ook na langdurige opslag in 
vloeibare stikstof De viabiliteit van het ontdooide beenmerg werd 
bepaald met behulp van donogene testen waarmee de van de 
beenmergstamcel afkomstige progemtorcellen gekwantificeerd worden 
De wijze van ontdooien van het beenmerg en de reproduceerbaarheid van 
de donogene testen werden verbeterd Dit laatste werd bereikt door 
het gebruik van geselecteerde colonie stimulerende factoren (CSF), 
noodzakelijk om in vitro de voorlopercellen te laten uitgroeien tot 
een kloon van rijpe cellen 
In hoofdstuk 2 wordt ЬеьсЬге еп dat met een discontinue celscheider 
een verdergaande verrijking van het beenmerg kan worden bereikt Het 
principe berust op dichtheidsverschillen tussen de diverse celtypen 
Deze semi-automatische procedure in de celscheider resulteert in een 
eliminatie van vrijwel alle erythrocyten en 80 Ό van de kernhoudende 
cellen zonder merkbaar verlies van repopulatie capaciteit Een 
dergelijke vergaande verrijking van het beenmerg is een voorwaarde 
voor de meeste methoden waarmee in vitro selectieve verwijdering van 
tumorcellen wordt nagestreefd 
De resultaten van ABMT bij 11 patiënten met een acute leukaemie en 8 
patiënten met een solide tumor zijn m hoofdstuk 3 beschreven In 3 
patiënten werd geen volledige repopulatie van het beenmerg verkregen 
Deze 3 patiënten hadden een recidief acute leukaemie en kregen een 
laag aantal progemtorcellen Ze overleden aan complicaties, voordat 
het geinfundeerde beenmerg kon gaan functioneren De 16 patiënten die 
4 
meer dan 2 10 CFU-GM/kg kregen gaven allen een volledig herstel van 
de becnmergfunctie te zien ABMT lijkt een veilige procedure indien 
het aantal en de viabiliteit van de beenmergstamcellen is gewaarborgd 
De zeer intensieve antitumor therapie had bij patiënten in een 
vergevorderd stadium van de ziekte weinig effect op de tumor De 
werkelijke waarde van ABMT zal moeten worden bepaald in prospectieve, 
gerandomiseerde studies, bij patiënten m een vroege fase van de 
ziekte en met een zeer geringe tumormassa 
In het tweede deel van dit proefschrift worden de resultaten 
beschreven van een aantal onderzoeken naar de waarde van 
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chemotherapeutica voor de selectieve verwijdering van tumorcellen uit 
beenmergaspiraten. Bestudeerd werd het verschil in gevoeligheid 
tussen normale en leukaemische donogene cellen voor de cytostatica 
cytosine arabinoside (Ara-C) en adriamycine (ADM). Allereerst werd 
nagegaan welke parameters bepalend zijn voor het bereiken van een 
maximaal verschil in cytotoxiciteit tussen gezonde cellen en tumor 
cellen. 
In hoofdstuk 4 wordt de mate van cytotoxiciteit beschreven van 
toenemende Ara-C concentraties en verschillende incubatietijden. Het 
effect op de clonogeniciteit na 1-uur blootstelling was, ook bij zeer 
hoge en in de patient haast niet te bereiken Ara-C concentraties, 
uitermate gering. Bij verlenging van de incubatietijd werd Ara-C in 
toenemende mate cytotoxisch. Deze toename in cytotoxiciteit werd 
echter negatief beïnvloed doordat er Ara-C inactivatie optrad tijdens 
de incubatie. Deze inactivatie bleek afhankelijk van de 
celconccntratie tijdons expositie; hoe hoger de celconcentratie des te 
meer inactivatie van Ara-C tot uracil arabinoside. Ook na langdurige 
blootstelling aan farmacologisch gezien zeer lage Ara-C concentraties, 
blijkt een aanzienlijke remming van de donogene cellen op te treden. 
In hoofdstuk 5 is het effect op donogene cellen van toenemende 
concentraties ADM beschreven na incubatie gedurende 5 minuten, 2 uur 
en 24 uur. De bereikte intracellulaire ADM concentraties werden per 
cel gemeten met behulp van fluoro-flowcytometrie. De gemeten 
intracellulaire ADM concentraties, die vergelijkbaar waren ongeacht of 
de incubatie had plaatsgevonden bij hoge ADM concentraties gedurende 
korte tijd, of lage ADM concentraties gedurende lange tijd, bleken 
gecorreleerd te zijn met de mate van remming van clonogeniciteit. Uit 
deze resultaten valt af te leiden dat de uiteindelijke ADM 
concentratie die intracellulair bereikt wordt bepalend is voor 
cytotoxisch effecten, niet de wijze van toediening of blootstelling 
aan ADM. 
In Hoofdstuk 6 is een model gepresenteerd voor de in vitro bestudering 
van de differentiële gevoeligheid tussen enerzijds normale 
beenmergcellen en anderzijds cellen van een leukaemische cellijn. Het 
cytotoxische effect van Ara-C na 1-uur blootstelling was voor zowel de 
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normale als de leukaemische donogene cellen beperkt, ondanks extreem 
hoge Ara-C concentraties Verlenging van de duur van blootstelling 
van 1-uur tot enkele dagen resulteerde en in een toename van de 
toxiciteit van ongeveer 100 maal en in een duidelijke differentiële 
gevoeligheid Een circa 100-voudige vermindering van het aantal 
leukaemische donogene cellen kon worden bereikt zonder 
noemenswaardige remming van de normale donogene beenmergcellen 
De differentiële gevoeligheid voor Ara-C van normale en leukaemische 
donogene beenmergcellen is beschreven in hoofdstuk 7 Ook op 
leukaemische donogene cellen had een 1-uurs expositie slechts een 
gering cytotoxische effect Verlenging van de expositieduur tot 5 
resp 10 dagen, waarbij tijdens de Ara-C blootstelling ook 
kolonie-stimulerende factoren werden toegevoegd, leidde tot een 
duidelijke remming van de clonogemciteit van beide typen cellen De 
gevoeligheid van de leukaemische donogene cellen voor Ara-C na een 
5-daagse expositie bleek bij 1 van de 8 beenmergmonsters aanzienlijk 
hoger te zijn dan die van de normale donogene cellen Na 10 dagen 
expositie ging dit op voor 4 van deze 8 beenmergmonsters Drie van de 
8 leukaemische monsters die zijn getest gaven zonder toevoeging van 
CSF spontane kolonievorming in agar Na een 5-daagse Ara-C incubatie, 
echter zonder CSF was de differentiële gevoeligheid voor met name deze 
3 monsters aanzienlijk Kennelijk is de mate van differentiële 
gevoeligheid voor Ara-C gerelateerd aan de proliferatieve activiteit 
van zowel de normale als de leukaemische donogene cellen Van dit 
fenomeen kan mogelijk gebruik gemaakt gaan worden voor de selectieve 
verwijdering van tumorcellen uit beenmerg 
De resultaten van bepalingen van de differentiële gevoeligheid voor 
ADM van normale en leukaemische donogene cellen zijn beschreven in 
hoofdstuk 8 De cellulaire ADM concentraties werden gerelateerd aan 
de remming van de clonogemciteit De variatie in cellulaire ADM 
concentraties in de diverse leucaemische en normale monsters waren 
zeer beperkt na eenzelfde blootstelling Ook de remming van de 
clonogemciteit was daarbij nauweliiks verschillend ADM is daarom 
met geschikt voor selectieve in vitro verwijdering van donogene 
tumorcellen uit beenmergaspiraten De intracellulaire ADM 
concentraties die cytotoxisch bleken te zijn voor de donogene cellen 
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in vitro werden daarnaast vergeleken met de cellulaire concentraties 
die na intraveneuze toediening van standaarddosenngen bij patiënten 
bereikt worden. Deze cellulaire concentraties kwamen maximaal overeen 
met de concentraties die in vitro leiden tot ongeveer 50 % remming van 
de donogene cellen 
CONCLUSIES 
De ontwikkelde aanpassingen in de procedure van ABMT, aangevuld met 
adequate kwaliteitscontroles, kunnen bijgedragen aan een veilige 
toepassing van ABMT 
ABMT bij patiënten in een vergevorderd stadium van de ziekte met 
veelal een zekere resistentie voor cytostatica en een grote 
tumormassa, is niet zinvol gebleken De eventuele tijdelijke gunstige 
effecten wegen niet op tegen de biiwerkingen van een dergelijke 
intensieve behandeling De indicaties voor ABMT dienen dan ook 
beperkt te worden tot vroege stadia van de ziekten en daarnaast dient 
ABMT pas uitgevoerd te worden nadat de tumormassa optimaal gereduceerd 
is Indien veer het verzamelen van beenmerg reeds beenmergtoxische 
behandeling heeft plaatsgevonden, is bepaling van de hoeveelheid 
resterende donogene cellen voorafgaande aan aspiratie zeker 
geïndiceerd Op basis van deze informatie is vast te stellen of 
voldoende stamcellen verzameld kunnen worden voor een verantwoorde 
ABMT 
Het onderzoek naar de differentiële gevoeligheid voor ADM en Ara-C 
heeft niet geleid tot een practisch toepasbare methode om beenmerg te 
zuiveren van tumorcellen ADM lijkt vooralsnog niet geschikt voor dit 
doel Met Ara-C kan mogelijk een selectieve verwijdering van 
tumorcellen worden bereikt indien gebruik kan worden gemaakt van 
verschillen in proliferatieve activiteit tussen normale en 
leukaemische donogene cellen De in vitro blootstelling dient dan 
langdurig te zijn en bij lage concentraties Ara-C te worden 
uitgevoerd Stoffen die selectieve stimulering van de proliferatie 
van de leukaemische cellen induceren zouden kunnen worden gebruikt om 
de verschillen m gevoeligheid voor Ara-C in vitro te vergroten, 
waardoor de efficiëntie van tumoreliminatie verbeterd kan worden. 
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CURRICULUM VITAE 
De auteur van dit proefschrift is geboren te Eindhoven op 18 september 
1955 als zoon van Leo Raijmakers en Mies Kubbmga Na het eindexamen 
Atheneum aan het lyceum Augustinianum in 1974, begon hij de studie 
Geneeskunde aan de Katholieke Universiteit te Nijmegen Het 
artsexamen werd behaald op 31 maart 1981 Tijdens zijn militaire 
dienst werd hi] gedetacheerd op de afdeling Hematologie van het 
St Radboudziekenhuis (hoofd prof Dr С Haanen) In die tijd was hij 
betrokken bij onderzoek betreffende beenmergtransplantatie De 
werkzaamheden op de afdeling Hematologie werden in juli 1982 
voortgezet middels een subsidie van het Koningin Wilhelmina Fonds 
(KWF) Het onderzoek gedaan tijdens deze subsidieperiode is 
vastgelegd in dit proefschrift In juli 1984 werd hij ingeschreven 
als internist in opleiding in de Kliniek voor Inwendige Ziekten van 
het St Radboudziekenhuis te Nijmegen (hoofd prof dr A van 't Laar) 
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STELLINGEN 
behorende bij het proefschrift van 
R RAIJMAKERS 
1. Met behulp van in vitro kweken van hematopoietische 
progenitorcellen is het repopulerend vermogen van gecryopreserveerd 
autoloog beenmerg te voorspellen. 
Dit proefschrift 
2. Geprogrammeerd invriezen van beenmerg in autoloog plasma garandeert 
een zeer hoge viabiliteit van de donogene cellen en daardoor een 
optimale kans op repopulatie. 
Dit proefschrift 
3. In vitro wordt het maximale verschil in cytosine arabinoside 
gevoeligheid tussen normale en leukemische donogene cellen bereikt 
bij langdurige blootstelling aan lage concentraties. Zowel in 
consolidatie schema's voor acute leukemie alsook bij in vitro 
eliminatie van leukemische blasten dient van dit gegeven gebruikt te 
worden gemaakt. 
Dit proefschrift 
4. Op grond van metingen van het concentratieverloop van adriaraycine 
in normale en leukemische blastaire cellen blijkt dat cellulaire 
piekconcentraties, welke optreden na kortdurende expositie, van geen 
belang zijn voor het uiteindelijke cytotoxische effect op donogene 
cellen. 
Dit proefschrift 
5. De duur en niet het al dan niet bereiken van een klinisch complete 
remissie dient gerelateerd te worden aan in vitro cytostatica 
gevoeligheid van donogene cellen om de predictieve waarde van deze 
gevoeligheidstesten aan te tonen 
Von Hoff et al; Am J Med 1981 70:1027-1032. 
6. Het adagium hoe meer hoe beter geldt mogelijk voor cytostatica maar 
zeker niet voor "biological response modifiers". 
7. Het is onjuist om bij een verhoogd serum cholesterolgehalte zonder 
nadere diagnostiek cholesterol verlagende maatregelen te adviseren. 
B. Radiotherapie, tot op heden voornamelijk gebruikt als 
loco-regionale behandeling, wordt van steeds groter belang als 
systeembehandeling, zowel bij de bestrijding van bepaalde vormen van 
gesystematiseerde kanker als ten behoeve van een immunosupressief 
effect. 
9 De waarde van plasmaferese in de behandeling van reumatoide 
arthritis is nooit aangetoond in gerandomiseerde studies, doch geeft 
goede resultaten in individuele patiënten Nader onderzoek naar de 
selectiecriteria voor deze patiënten is noodzakelijk om de 
uiteindelijke waarde van plasmaferese te bepalen 
R Raijmakers, A Boerbooms, L van de Putte, Τ de Witte, 
Neth J Med 1984 27 65-68 H Nuver-Zwart, A Boerbooms, 
Τ de Witte, Neth J Med, in press 
10 Bij vrouwen met onverklaarde vruchtdood dienen antilichamen 
gericht tegen cardiolipme te worden bepaald 
Lockshm et al, N Eng J Med 1985 313 152-156 
11 Beeldcommunicatie, een vorm van kinder- en jeugdpsychotherapie, is 
door het specifieke gebruik van het verbeeldend vermogen bij uitstek 
geschikt als behandelingsmethode voor kinderen die ten gevolge van een 
onverwerkt rouwproces in hun ontwikkeling zijn vastgelopen 
Thea Donker-Raijmakers, Beeldcommunicatie in rouwverwerking, 
in Therapie, kind en spel, ν Lochern Slaterus, Leiden, 1985 
12 De geschiedenis van de geneeskunde leert dat wanneer de oorzaak 
van een ziekte niet duidelijk vaststaat, men geneigd is naast de 
opvattingen uit de vigerende ziekteleer steeds betekenis toe te kennen 
aan goddelijk ingrijpen, voorbeschiktheid, erfelijkheid, 
miasmatisch-tellunsche invloeden, contagia, dieetfouten of een 
bepaalde karakterstructuur 
13 Een holistische benadering van de chronische pijn bij terminale 
patiënten impliceert naast aandacht voor de somatische aspecten tevens 
aandacht voor sociale isolatie, het afhankelijk worden van anderen en 
het verlies van fysieke vermogens 
14 De meeste wijn verdient met geproefd, doch slechts gedronken te 
worden 



